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The kallikrein-kinin system (KKS) is a protein system in which the serine proteases, tissue
kallikrein (TK) and plasma kallikrein (PK), cleave kininogen substrate to release the kinins,
kallidin and bradykinin, respectively. Kinins act on bradykinin receptor subtype 1 (B1R)
and bradykinin receptor subtype 2 (B2R) to induce vasodilation, increase vascular
permeability, promote cell proliferation, regulate cell migration and upregulate proteolytic
activity. TK may also cleave and activate matrix metalloproteinases, thereby enhancing
proteolytic activity.
The KKS has been shown to play an important role in inflammation and angiogenesis.
These processes are vital to the development of cancers, thereby implicating the KKS in
cancer pathology. There is evidence that the KKS specifically contributes to the
development of prostate and breast cancer. Previous studies have shown involvement of the
KKS in the proliferation, migration and invasion of prostate and breast tumour cells, as well
in the growth of prostate tumours in vivo possibly, in part, via promotion of angiogenesis. In
some of these studies, hormone-independent prostate and breast tumour cells were used,
thereby implicating the KKS in the progression of such cancers, for which therapy is
currently inadequate. Thus, the present study aimed to further elucidate the role of the KKS
in prostate and breast tumour progression with particular reference to angiogenesis.
Materials and Methods
Dermal microvascular endothelial cells (dMVECs), DU145 prostate tumour cells and MCF7
breast tumour cells were grown in culture. An in vitro challenge model was set up whereby
these endothelial and tumour cells were challenged with conditioned medium from tumour
and endothelial cells, respectively, at concentrations of 10%, 25% and 50%. The expression
of the KKS proteins, TK, B1R and B2R, was then investigated in cells of the challenge
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model, while secretion of TK into the surrounding media was also measured. The KKS
proteins were localised in unchallenged and challenged cells using the avidin-biotin complex
(ABC) immuno-detection system with peroxidase-diaminobenzidine (DAB) as the enzyme-
substrate combination. This was followed by quantification of the intensity and extent of
KKS staining, using image analysis, to determine the effect of challenge metabolites on
intracellular KKS levels. The effect of challenge metabolites on TK secretion was analysed
by performing a TK enzyme-linked immunoassay (ELISA) on media collected from
unchallenged and challenged cells. Additionally, the effect of challenge metabolites on cell
proliferation in culture was measured by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide (MTT) cell proliferation assay. An endothelial-tumour cell co-culture
model was also set up, in which the morphology of cell interactions was observed and in
which KKS proteins and cell-specific marker proteins were co-localised using ABC-DAB
and alkaline phosphatase-fast red immuno-detection systems.
Results
TK, B I R and B2R were immuno-localised in the cytoplasm, membranes and projections of
unchallenged endothelial cells, as well as in the same areas of those endothelial cells
challenged by tumour cell metabolites. Such localisation was also evident in small
projections of endothelial cells that were involved in initiating endothelial cell-cell contact.
There was a significant decrease in intracellular TK in endothelial cells challenged with both
types of tumour cell metabolites, and this effect was greater as the challenge concentration
increased. Immuno-reactive B1R and B2R levels in endothelial cells were not significantly
affected by exposure to tumour metabolites. TK was undetectable in the medium of
unchallenged endothelial cells. However, when these cells were challenged with increasing
concentrations of tumour metabolites, this protein was detected in increasing amounts.
Similarly, endothelial cell proliferation significantly increased with increasing challenge
concentrations.
TK, B 1 R and B2R were immuno-localised in the cytoplasm and projections of prostate and
breast tumour cells. While TK, BIR and B2R levels in breast tumour cells were not
significantly affected by exposure to endothelial metabolites, in challenged prostate tumour
cells there was an overall decrease in intracellular TK, BIR and B2R. Both unchallenged prostate
and breast tumour cells secreted TK into their respective media and this activity was not
significantly influenced by exposure to endothelial metabolites. Similarly, the proliferation of
challenged tumour cells did not differ significantly from that of unchallenged counterparts.
In co-cultures, tumour cells formed footplate-like connections with endothelial cells and
occasionally endothelial cell projections formed contact with tumour cells. TK, B 1 R and
B2R were immuno-localised in both endothelial and tumour cells at these points of
interaction. In the presence of tumour cells, endothelial cells tended to increasingly connect
with one another to form chain-like or circular structures.
Discussion
This study showed that KKS proteins were present in, and TK was secreted by, prostate and
breast tumour cells. In addition, the metabolites of both these tumour types increased the
secretion of TK from endothelial cells, while there were corresponding decreases in
intracellular TK. These findings point to an upregulation of proteolytic activity and kinin
generation in prostate and breast tumour environments. Upregulation of these activities may
promote tumour-associated angiogenesis by stimulating or facilitating endothelial cell
proliferation, migration and invasion of the extracellular matrix (ECM) and capillary tube
formation. The role of the KKS in these steps of the angiogenic cascade is additionally
supported by the results of the present study. The concomitant increase in TK secretion
from, and proliferation of endothelial cells that were challenged with tumour metabolites,
suggests possible involvement of the KKS in endothelial cell proliferation. Further, the
presence of the KKS in large projections (i.e. the leading edge of movement) of endothelial
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cells may indicate a role for the KKS in endothelial cell migration and invasion of the ECM.
The KKS proteins were also localised in small projections of endothelial cells that were
involved in initiating endothelial cell-cell contact, which is required for capillary tube
formation. Thus, an upregulation of TK in prostate and breast tumour environments may
promote prostate and breast tumourigenesis via stimulating angiogenesis in these tumours.
Further supporting this hypothesis was the presence of the KKS in tumour-endothelial cell
points of contact as well as the fact that, when these two types of cells were cultured
together, the endothelial cells formed primitive structures suggestive of angiogenesis.
Upregulation of proteolytic activity and kinin generation in the tumour environment may
also enhance tumourigenesis via mechanisms other than the upregulation of angiogenesis.
Proteolytic activity and kinins have been shown to promote prostate and breast tumour cell
proliferation, migration and invasion. The role of the KKS in migration and invasion of
these tumour cells is supported by the localisation of the KKS proteins in tumour cell
projections in the present study. Further, since kinin signalling may potentiate that of growth
factors important in the development of hormone-independent prostate and breast cancer,
increased kinin generation in these tumour environments, as suggested by the present study,
supports a role for the KKS in the development of hormone independence. Another
consequence of increased kinin generation in prostate and breast tumour environments
would be enhancement of inflammation in the stroma of these tumours, which would then
additionally contribute to tumour progression.
Conclusion
The study supports an important role for the KKS in prostate and breast tumourigenesis and
tumour-associated angiogenesis and there is, as a result, a possibility that KKS antagonists
may be useful in the treatment of these cancers, including advanced, hormone-independent
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1.1 Cancer, angiogenesis and the kallikrein-kinin system
1.1.1 Cancer
1.1.1.1 Historical background and definition of cancer
Some of the first references to cancer can be found in Egyptian papyri that were written
between 1500-3000 BC (1, 2). Since then, ideas of what cancer is and what causes cancer
have been changing and developing. The term 'cancer' originated when Hippocrates (460-
370 BC) likened the appearance of a breast tumour to that of a crab, the Latin word for
which is cancer (3, 4). Hippocrates thought that cancer was caused by an excess of black
bile, which was one of the 4 body humours described at the time — blood, phlegm, yellow
bile and black bile (1). By the 17 th century this theory was no longer accepted and the focus
shifted to lymph as the source of cancer (3, 4). Following the discovery of cells by Robert
Hooke in 1665 and the development of the concept of tissues by Xavier Bichat (1771-1802),
it was thought that cancer was derived from cellular tissue (1, 4) and this was subsequently
established by Johannes Mueller (1801-1858) (3). A pupil of Xavier Bichat, Rene Laennec
(1781-1826), first distinguished inflammatory conditions from that of true tumours (4).
However, the association between inflammation and cancer (first realised by the ancient
Greeks) continued to be recognised (4) and is still acknowledged today (Section 1.1.1.3). In
the nineteenth century, Rudolph Virchow established that each cell arises from the growth
and division of other cells (1, 3) and he suggested that tumours develop from immature cells
in connective tissue (5). Remak (1815-1865) extended Virchow's theory by dividing
tumours into two classes viz. those that arise from epithelial cells (carcinomas; the majority
of tumours) and those that arise from mesenchymal/non-epithelial tissue (sarcomas) (5, 6).
Next, Wilhelm Waldeyer (1836-1921) significantly contributed to our current understanding
of cancer by (i) suggesting that tumours arise from cells transformed by external factors, and
(ii) establishing that tumour cells metastasise via lymphatic and blood vessels (4).
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At present, two features define cancer viz. (i) unregulated proliferation of cells to form a
tumour and (ii) the ability of these cells to invade tissues outside of the original compartment
of growth and metastasise to organs distant from the site of origin (7). The latter
characteristic distinguishes a malignant tumour from a benign tumour (7).
1.1.1.2 Tumour initiation, progression and metastasis
The development of a malignant tumour occurs in stages. These stages, using epithelial
tissue as an example, are typically: hyperplasia, dysplasia, in situ carcinoma and invasive
carcinoma. The triggering of this process and the progression from one stage to the next,
finally resulting in the malignant phenotype, is the result of genetic mutations in cells.
Mutations may be as a result of external factors, such as chemicals, viruses and radiation, or
endogenous factors, such as inherited mutations and errors of DNA replication (7, 8).
Hyperplasia, an increase in the number of cells, is due to mutations that convert proto-
oncogenes to active oncogenes (8). Proto-oncogenes usually code for proteins that promote
initiation of, and progression through, the cell cycle. These include growth factors or their
signalling proteins, transcription factors and cyclins (7, 9). Proto-oncogenes become
oncogenic when mutations cause their upregulated expression or the expression of an active
form of the encoded protein in the absence of its activators. For example, the erb-b
oncogene encodes a form of epidermal growth factor (EGF) receptor that is activated in the
absence of EGF (9).
The mutation of proto-oncogenes to oncogenes is not, however, sufficient for tumour
progression. This is due to protective cell cycle G 1 /S and G2/M checkpoints that halt
progression of the cell cycle from the G1 to S phase and G2 to M phase, respectively, when
DNA is damaged/mutated. If the damage is too severe to be repaired, apoptosis or
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programmed cell death is induced. Mutations in tumour suppressor proteins, that are usually
checkpoint proteins, DNA repair proteins or apoptotic regulators, allow for the proliferation
and accumulation of cells with oncogenic mutations (7). For example, more than 50 % of
human cancers have anti-apoptotic mutations in the checkpoint protein p53 (8).
Accumulation of anti-apoptotic mutations in tumours negatively affects the effectiveness of
conventional cancer therapies (10).
Increasing dysregulation of cell growth, which results in continued proliferation of cells,
prohibits differentiation and results in the buildup of undifferentiated cells (11). Mutations
may also accumulate in genes that control differentiation, such as those that control cell-cell
and cell-extracellular matrix (ECM) interactions (11). As these mutations accumulate, the
abnormal mass of cells progresses from the hyperplasia to dysplasia stage, in which tumour
cells appear different from cells of the surrounding tissue. They are undifferentiated, have a
disorganised arrangement and exhibit morphologic changes in their nuclei (12). With further
mutations, the growth and appearance of tumour cells becomes increasingly abnormal and
the tumour acquires invasive capacity. At this stage, if the tumour has not yet grown beyond
the borders of its original compartment, it may be classified as an in situ carcinoma (8).
Several mutations are required before a tumour cell has the capacity to invade tissues outside
of the original compartment of growth and metastasise to sites distant from the site of origin.
In order to acquire the malignant phenotype, a tumour cell must progressively acquire
mutations that sequentially allow it to (i) detach from the solid tumour, (ii) escape anoikis
(apoptosis triggered by the loss of cell adhesion to the extracellular matrix [ECM]),
(iii) invade and migrate within the ECM, (iv) enter the circulation, (v) escape immune
surveillance in the circulation, (vi) adhere to endothelial cells and exit lymph or blood
vessels into the tissue of the target organ (13). These are discussed in detail below.
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(i) Decreased cell-cell adhesion not only results in loss of differentiation but also allows for
detachment of cells from the tumour. E-cadherin is the main molecule involved in cell-cell
adhesion (14) (Section 1.1.2.6.2). Mutations in E-cadherin have been demonstrated in
human carcinomas, including breast and prostate cancers, and are associated with
invasiveness in these cancers (15-17). Disruption of cell-cell contacts may also be achieved
by proteolysis of cell adhesion systems by matrix metalloproteinases (MMPs) (18) and the
urokinase plasminogen activation (uPA) system, which are upregulated in
cancer (19, 20) (Section 1.1.3.1 and 1.1.3.2).
(ii; iii) Invasion of the ECM also requires disruption of cell-ECM adhesions (21) (Section
1.1.2.6.1). Integrins are mostly responsible for adhesion of cells to the ECM and disruption
of this adhesion usually leads to apoptosis/anoikis (22) (Section 1.1.2.6). Cancer cells,
including those of breast and prostate, frequently have altered integrin composition and
function to allow decreased substrate attachment and survival (23 -25). Certain integrins,
such as cc6134 and a5131, promote survival of carcinoma cells and may be upregulated by
tumour cells (25-27). Migration within the ECM also requires removal of ECM barriers to
invasion, which is achieved by proteolysis (28). Matrix metalloproteinases and the uPA
system are important for breast cancer invasiveness (29) and MMPs enable invasion of
basement membrane by prostate epithelial tumour cells (30). Mobility of tumour cells may
be promoted by proteases (31) (Section 1.1.3.1, 1.1.3.2 and 1.1.3.3.2.2.3) or mutations that
upregulate activity of mobility factors. For example, receptors for scatter factor (SF) and
autocrine mobility factor are dysregulated in prostate cancer to facilitate mobility of
cells (32, 33).
(iv) Tumour cells may overexpress vascular endothelial growth factor-C (VEGF-C), which
increases the diameter of lymphatic vessels, thereby increasing the surface area for
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metastasis (34). The structure of tumour vessels that arise from angiogenesis (may be
induced by pro-angiogenic mutations) also facilitates extravasation (35) (Section 1.1.2.1 ).
(v) Mutations that increase sialylation of carbohydrates on the tumour cell membrane
promote immunologic escape in the circulation (13) and increase the binding of circulating
tumour cells to endothelial cells (36). Downregulated expression of class I major
histocompatibility complex, which is involved in antigen presentation, has been identified in
prostate cancer (37).
(vi) Lastly, tumour cells must further acquire the ability to disrupt endothelial intracellular
adhesions in order to exit the circulation into tissues where they may proliferate to form a
new tumour. Sandig et al. (1997) demonstrated the disappearance of VE-cadherin in
endothelial cells in contact with melanoma cells, the intercalation of tumour cells between
these endothelial cells and the re-forming of these adhesions once the tumour cells had
passed through the endothelium (38). Induction of angiogenesis is also required for tumour
cells to proliferate in the target tissue (39) (Section 1.1.2.1). Once the tumour has invaded
the surrounding connective tissue it is classified as an invasive carcinoma (8). Refer to
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1.1.1.3 The role of the tumour microenvironment and inflammation in tumour
progression and metastasis
Solid tumours may be described as having two compartments viz. parenchyma (tumour cells)
and stroma. Stroma consists of non-cellular ECM components, fibroblasts, inflammatory
cells (present as an inflammatory reaction to tumour cells) and blood vessels. Tumour cells
induce stroma formation by increasing vascular permeability. This is usually mediated by
VEGF, which is secreted by the majority of human tumours. Leakage of plasma results in
extravascular clotting and, consequently, the formation of a fibrin network that attracts
fibroblasts (a major source of non-cellular ECM) and forms a framework for the
development of new blood vessels by angiogenesis (12). The crosslinked fibrin formed is
chemotactic for inflammatory cells (31) and the clotting cascade also results in production of
pro-inflammatory products (40), resulting in infiltration of inflammatory cells. The stroma
plays a vital role in tumour progression (41 -43). A discussion of the role of these stromal
factors, listed in Figure 1.1, in tumourigenesis follows.
Proteases are required for tumour metastasis as described in Section 1.1.1.2. In some
cancers, such as breast ductal carcinoma, the source of these proteases is mainly the stromal
cells, namely fibroblasts, macrophages and pericytes, rather than the tumour cells (41).
Experiments performed with transplanted MMP-2 expressing Lewis lung carcinoma cells
resulted in reduction in lung metastasis in MMP-2 deficient mice when compared with
normal mice, thereby demonstrating the importance of stromally-generated proteases in
cancer (44).
As discussed in Section 1.1.1.2, the modulation of cell-ECM adhesions occurs with tumour
progression and is necessary for metastasis. Modification of the non-cellular ECM and the
effect this has on cell behaviour (refer to Section 1.1.2.5) also contributes to
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tumourigenesis (45). Mutations in genes encoding ECM components are associated with the
development of certain types of tumours, such as smooth muscle tumours (46). The ECM in
conjunction with proteases also regulates growth factor availability (31, 47, 48) (Section
1.1.2.5) and growth factors contribute to tumour progression (49) (Section 1.1.3.3.2.6.2).
The inflammatory reaction present in the tumour stroma provides a favourable environment
for tumour progression (31, 42, 43). O'Byrne and Dalgleish (2001) describe the nature of
this inflammatory environment as chronic (43). If it precedes tumour formation, the risk of
random mutations and tumour formation is increased !due to increased reactive oxygen
species and a tolerant environment for tumour progression; (43)]. Supporting this are the
links observed between schistosomiasis and bladder cancer, Helicobacter pylori and stomach
cancer and fibrosis of the breast and breast cancer (50-52). Whether or not a chronic
inflammatory type of environment is present prior to tumourigenesis, tumour cells may
interact with their environment to induce this favourable state (42), which O'Byrne and
Dalgleish (2001) argue is necessary for tumour progression (43).
An environment of chronic inflammation facilitates tumour progression through decreasing
immune surveillance, promoting cell proliferation, decreasing apoptosis and promoting
angiogenesis (43). In an environment of chronic inflammation, T helper 2 cell (Th2)
cytokines predominate over Thl cytokines (43). An initial response is Thl predominant i.e.
T helper 1 cells produce proinflammatory cytokines (43). These cytokines upregulate cell
mediated immunity (CMI), which is mainly responsible for host attack on tumour cells (43).
However, Th 1 cytokines also induce expression of cyclo-oxygenase-2 (COX-2) by
epithelial, mesenchymal and inflammatory cells (53). Cyclo-oxygenase-2 results in the
upregulation of Th2 cytokines, which then suppress Thl cytokine production and therefore
CMI (43). In a Th2-predominant environment, growth factors that promote cell proliferation
10
are upregulated e.g. insulin-like growth factor 1 (IGF-1) (43). Anti-apoptotic factors are also
upregulated e.g. macrophage inhibitory factor (MIF) is expressed which represses
transcription of pro-apoptotic p53 (54). The Th2-predominant environment is also pro-
angiogenic as Th2 cytokines stimulate macrophages to release factors that promote vascular
endothelial growth (55). Tumour cells may induce this environment through constitutive
upregulation of COX-2, which has been demonstrated in a wide range of premalignant
lesions and tumours (43). Supporting the role of chronic inflammation in tumourigenesis are
studies that show inhibition of tumour growth by specific COX-2 inhibitors (53, 56).
The contribution of cellular and non-cellular ECM components and cell adhesions to blood
vessel growth by angiogenesis is described in Sections 1.1.2.4-1.1.2.6, and the role of the
blood vessel stromal component in tumourigenesis follows.
1.1.2 Angiogenesis
1.1.2.1 The role of angiogenesis in tumour progression and metastasis
In 1971, Folkman proposed that, in the absence of neovascularisation, primary tumours and
metastases cannot expand beyond 1-2 mm 3 (57). Since then, considerable evidence has
amounted to prove his theory and it has been demonstrated that an increased blood supply,
achieved through neovascularisation, is required to provide adequate oxygen and nutrients as
well as waste removal in a growing tumour (39).
Mechanisms of blood vessel growth include arteriogenesis, vasculogenesis and angiogenesis.
Arteriogenesis is a process whereby vessels enlarge and become capable of bypassing
occluded vascular segments (58). Vasculogenesis involves the differentiation of angioblasts
into endothelial cells that then assemble into a vascular network and may occur in both the
embryo and the adult (59). Angiogenesis may be defined as the sprouting of new capillary
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blood vessels from pre-existing postcapillary venules (39, 58) and remains the primary
mechanism by which new blood vessels arise in the adult (59).
In tumours, more than one mechanism of blood vessel growth occurs. While it is not known
whether arteriogenesis contributes to the development of a tumour's blood supply (60), in
some tumours, such as aggressive primary or metastatic cutaneous melanomas, a process
similar to vasculogenesis occurs. In these tumours, the tumour cells themselves form a
microvascular network. Thus, as in vasculogenesis, blood vessels are formed de novo by
this mechanism. However, this is not true vasculogenesis, as endothelial cells do not form
part of the newly formed blood vessels, hence the term "vasculogenic mimicry" (61).
Vasculogenic mimicry explains the lack of angiogenesis in melanomas (59). Another
vasculogenesis-like process is the recruitment of circulating endothelial progenitor cells to
tumours with subsequent differentiation in the stroma and incorporation into new blood
vessels (62). However, this process is angiogenesis-dependent as it relies on angiogenesis-
promoting factors to recruit the cells and induce their differentiation (62). Angiogenesis is
thought to be the main mechanism by which tumours increase their blood supply. It is
generally accepted that most tumours are angiogenesis-dependent and are required to make a
pro-angiogenic "switch" to progress, as Folkman proposed (39, 63).
Angiogenesis not only promotes tumour growth through increasing the blood supply, but
also by the production of tumour growth factors by angiogenic endothelial cells. These
factors include platelet-derived growth factor (PDGF), IGF-1, SF, granulocyte colony
stimulating factor (GCSF) and interleukin 6 (IL-6) (64).
Although the lymphatic system is also a route for metastasis (Section 1.1.1.2), blood vessels
are the major entry point into the circulation for tumour cells (39). Angiogenesis facilitates
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the beginning of metastasis by increasing the number of blood vessels. thereby increasing the
number of tumour cells that enter the circulation (39), a small percentage of which
metastasise (64). In addition, the entry of tumour cells into the circulation is facilitated by
the disrupted basement membranes in tumour vessels that arise by angiogenesis (39, 65).
Lastly, metastases will remain as micrometastases in a dormant state unless they switch to
the pro-angiogenic phenotype and recruit their own blood supply (66).
The -angiogenic switch" is of great clinical importance as it is usually metastases (largely
angiogenesis-dependent) that cause lethality (64). Folkman (2002) suggests that
angiogenesis is so central to metastasis that failure of some tumours to make the "angiogenic
switch" can probably explain the infrequency of metastasis (67).
1.1.2.2 Overview of the angiogenic cascade
The events of the angiogenic cascade, as reviewed by Liekens et al. (2001), include
i) activation of endothelial cells, ii) release of proteases (MMPs and uPA, Sections 1.1.3.1
and 1.1.3.2) from activated endothelial cells, iii) subsequent degradation of the underlying
basement membrane, iv) endothelial cell invasion of, and migration into, the ECM,
v) endothelial cell proliferation, and vi) differentiation of endothelial cells into mature blood
vessels (68). The last step involves the assembly of endothelial cells into cords, the
subsequent formation of a lumen and differentiation of endothelial cells into quiescent cells
with specialised characteristics. Vascular myogenesis, a process whereby vascular pericytes
and smooth muscle cells are recruited, is also part of vessel maturation (58).
Angiogenesis occurs during foetal development. In the adult, angiogenesis is induced during
exercise-induced muscle growth (39), wound healing, the female menstrual cycle, and in a
number of pathological processes, such as rheumatoid arthritis, diabetic retinopathy,
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psoriasis, juvenile haemangiomas and tumourigenesis (68). Angiogenesis is induced by
deficiencies in glucose and oxygen that result from an increased volume of cells (69).
Maxwell et al. (1997) demonstrated that hypoxia is a major trigger of angiogenesis (70).
These investigators found that induction of angiogenesis by hypoxia is mediated through
upregulation of hypoxia inducible factor-I (111F-1), which then induces expression of the
pro-angiogenic factor, VEGF. Disruption of the balance of angiogenic factors in favour of
pro-angiogenic factors (either by an increase of pro-angiogenic factors or a decrease of anti-
angiogenic factors) activates endothelial cells and initiates angiogenesis (63, 66).
These angiogenic regulatory factors are produced by cells of the ECM and they influence
angiogenesis by acting directly on the endothelial cells or through modification of the ECM
and cell adhesions. These modifications are mainly mediated by proteases, the production of
which (by endothelial cells and cells of the ECM) is under control of angiogenic regulatory
factors. This modulation of the endothelial cell environment directs its activities in order to
achieve the formation of a new capillary network (71). The endothelial cell appears to
express all the information necessary to form this network (71). A discussion of the
regulation of angiogenesis, under the topics of angiogenesis regulators, ECM components,
cell adhesions and proteases, follows (Sections 1.1.2.3-1.1.3.2 and 1.1.3.3.2.5) and is
summarised in Figure 1.2.
1.1.2.3 Regulators of angiogenesis
1.1.2.3.1 VEGF
In the 1980s, vascular permeability factor (VPF), a dimeric glycoprotein that increases
vascular permeability, was identified in rodent tumour lines and purified from serum-free
conditioned medium of a human lymphoma cell line (72). Subsequently, Ferrara and Henzel




induced endothelial cell proliferation (73). They named it VEGF. The sequence of VEGF
was identical to that of VPF i.e. they were found to be the same. Since then five
isoforms (39) and five homologs of VEGF have been recognised (Table 1.1). Several pro-
angiogenic functions of VEGF have been identified. Vascular endothelial growth factor
triggers expression of uPA, uPAR (uPA receptor) and PAI (uPA inhibitor), and the MMP,
collagenase, in endothelial cells (74, 75). (Refer to Sections 1.1.3.1 and 1.1.3.2 for the role
of these proteases in angiogenesis.) It also increases vascular permeability by induction of
endothelial fenestrations (76) and induces vasodilation (77). The isoforms of VEGF are also
involved in differentially determining the extent of vascularisation and the pattern of
connection of new vessels with the existing vasculature (78). In addition, VEGF (via
activity of different isoforms) is important in the regulation of lumen diameter, survival of
endothelial cells and possibly their differentiation into fenestrated endothelium in endocrine
glands (58). Thus, VEGF acts at all stages of angiogenesis. Vascular endothelial growth
factor mediates these angiogenic effects via binding to its receptors, namely Flt-1 (VEGFR-
1) and Flk-1 (VEGFR-2) (68). Nitric oxide synthase (NOS) activation is mediated by
VEGF and is necessary for VEGF-induced angiogenesis (79). Several studies using animal
models have demonstrated the potent induction of angiogenesis in vitro and in vivo by
VEGF (80). Additionally, VEGF inhibitors, including soluble Flt-1 and Flk-1 receptor
chimeric proteins, inhibit angiogenesis (80).
Evidence suggests that VEGF plays a key role in tumour angiogenesis (81). Maxwell et al.
(1997) demonstrated that HIF-l-mediated induction of VEGF following hypoxia is a major
contributor to tumour angiogenesis and therefore tumour growth (70). High levels of VEGF
expression have been identified in the majority of human tumours (81). It is thought that the
characteristically leaky tumour vessels with disrupted basement membranes can be attributed
to VEGF overexpression in tumours (65).
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Table 1.1 The role of pro- and anti-angiogenic regulatory factors in angiogenesis
Angiogenic
factors
Role in angiogenesis References
PIGF and • May form angiogenic heterodimers with VEGF. (82)
VEGF-B • Contribute to endothelial mitogenesis. (83. 84)
VEGF-C • Capable of inducing angiogenesis in vivo. (85)
• Primarily lymphangiogenic. (86)
VEGF-D • May induce angiogenesis in vivo. (87)
orf virus • Plays a role in dermal angiogenesis that arises when infected (88)
VEGF with the orf virus.
bFGF and • Stimulates endothelial cell proliferation and migration in vitro. (39)
aFGF • bFGF promotes capillary tube formation in vitro. (68)
• bFGF induces uPA expression by endothelial cells. (89)
• bFGF is increased in tumours and may be important for tumour
angiogenesis.
Ang- 1 • Promotes maturation of blood vessels (39)
• Stimulates endothelial production of PDGF, which mediates
recruitment of pericytes and smooth muscle cells
Ang-2 • Destabilises blood vessels by acting as an antagonist of ang-1. (39)
• Ang-2 in conjunction with VEGF increases angiogenesis.
Scatter factor • Promotes endothelial migration, proliferation and capillary tube
formation in vitro.
(90)
• Induces angiogenesis in vivo.
TGF-p • Induces angiogenesis in vivo. (91)
TNF • Involved in the activation of endothelial cells in vitro. (92)
• Necessary for VEGF-induced vascular permeability in vitro and
in vivo.
(93)
• Pro-angiogenic in vivo.
IL-6 • Acts synergistically with TNF to stimulate endothelial cell
migration.
(90)
IL-8 • May contribute to angiogenesis through chemotaxis of
inflammatory cells.
(94)
oestrogen • Stimulates angiogenesis in vitro. (95)
• Upregulates MMPs, VEGF and VEGFR. (96)
IGF-1 • Can promote differentiation and mobilisation of endothelial
progenitor cells.
(58)
TSP • TSP-1 is considered to be the main physiological angiogenic (68)
inhibitor. (97)
• Increased TSP-I production by macrophages inhibits tumour
angiogenesis.
(98, 99)
• TSP-2 potently inhibits tumour angiogenesis and tumour growth.
Angiostatin • A plasminogen fragment. (100)
• Inactivates ATPases thereby inhibiting endothelial cell migration
and proliferation.
(101)
• Its secretion by primary tumours suppresses growth of
micrometastases by inhibiting angiogenesis.
Endostatin • A fragment of collagen. (102)
• Inhibits endothelial cell proliferation and migration. (103)
• Its secretion by primary tumours suppresses growth of
micrometastases by inhibiting angiogenesis.
PIGF - placenta growth factor; orf virus/VEGF-(B, C, D) - orf virus/vascular endothelial growth factor-(B, C, D); VEGFR - vascular
endothelial growth factor receptor; bFGF - basic fibroblast growth factor; aFGF - acidic fibroblast growth factor; ang-(1, 2) - angiopoetin-
(1, 2); PDGF - platelet derived growth factor; TGF-C3 - transforming growth factor-(3; TNF - tumour necrosis factor; IL-(6, 8) - interleukin-




Cyclo-oxygenasc-1 and COX-2 are enzymes that produce prostaglandins from arachidonic
acid. The COX enzymes lie downstream of VEGF and are required for its pro-angiogenic
actions (104, 105). These enzymes are not only important mediators of angiogenesis, but
COX-2 is a key mediator of chronic inflammation and is associated with
tumourigenesis (Section 1.1.1.3). Thus, COX-2 links angiogenesis, inflammation and
cancer. In Section 1.1.2.4.1, the link between angiogenesis and diseases associated with
chronic inflammation [such as cancer (43)] is further discussed.
1.1.2.3.3 Other regulators of angiogenesis
The activities of the other pro - and anti -angiogenic factors are summarised in Table 1.1.
1.1.2.4 Cells of the ECM
1.1.2.4.1 Inflammation and angiogenesis
Angiogenesis and inflammation are closely associated (106, 107). Not only do blood vessels
formed by angiogenesis nurture the inflammatory region but activated angiogenic
endothelial cells of these blood vessels produce cytokines, such as IL-8, that promote tissue
infiltration by inflammatory cells (94) (Table 1.1). Activated endothelial cells also
contribute to inflammatory cell recruitment by upregulating expression of leucocyte
adhesion molecules (94). Inflammatory cells participate in the initiation and maintenance of
angiogenesis whether it be in wound healing or chronic inflammatory diseases (97, 107).
This participation in angiogenesis is described in Section 1.1.2.4.2. The simultaneous
existence of pathological angiogenesis and inflammation in several disease states, including
psoriasis, rheumatoid arthritis, chronic inflammatory bowel disease and cancer (97), and the
concomitant attenuation of these processes in arthritis by a single inhibitor, kallistatin,




Macrophages are differentiated monocytes (109). They are increased in regions of
angiogenesis (110) and play a key role in mediating this process (64). Hypoxia triggers the
expression of angiogenic factors, such as VEGF, in macrophages (107, 111). The
production of TNF-a and IL-la by macrophages can stimulate endothelial production of
MMPs, contributing to angiogenesis (112). Some factors produced by macrophages, namely
bFGF, PDGF and TNF-a, may upregulate tumour cell production of VEGF, specifically
contributing to tumour angiogenesis (13). Macrophages themselves are a source of
proteolytic factors, including matrix metalloproteinases and serine proteases such as elastase
and uPA, during angiogenesis (113). Via proteolytic cleavage of the ECM and also
production of ECM components, macrophages can modify the ECM (113), thereby
influencing angiogenesis (Section 1.1.2.5). Macrophages may also produce angio-inhibitory
TSPI (97). Failure of macrophages to switch to an anti-angiogenic phenotype, positively
contributes to tumour angiogenesis and vascular proliferation in chronic inflammatory
diseases such as psoriasis (97). In fact, evidence suggests that macrophages are a large
contributory factor to pathological angiogenesis (97).
1.1.2.4.2.2 Other leucocytes: T cells and granulocytes
Leucocytes produce several cytokines and in vitro studies show that they are capable of
inducing vascular proliferation and angiogenesis (97, 106, 114, 115). Cytokines produced
by leucocytes may activate macrophages, which subsequently promote angiogenesis (64).
For example, granulocyte monocyte colony stimulating factor (GMCSF; produced by
neutrophils) and interferon-y (INF-y; produced by T cells) are capable of activating
macrophages (64). The cytokines, TNF-a, IL-la and INF-y (released by leucocytes and
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macrophages), upregulate CD40 ligand (CD4OL) on vascular endothelium and smooth
muscle cells (116). Contact between CD4OL on activated T cells and CD4OL on vascular
endothelial cells promotes angiogenesis via upregulated expression of MMPs and also
stimulation of capillary tube formation (117). Cytokines produced by Th 1 cells induce
COX-2, which is a key mediator of chronic inflammation and angiogenesis (Sections 1.1.1.3
and 1.1.2.3.2).
Mast cells are connective tissue cells that may be derived from basophils (a type of
granulocyte). Mast cells mediate inflammation via the release of vasoactive agents, such as
histamine (109), thereby contributing to angiogenesis (107).
1.1.2.4.3 Fibroblasts
Fibroblasts may participate in inflammation, and thereby promote angiogenesis, via release
of cytokines with neutrophil and monocyte chemotactic activity on appropriate
stimulation (118). Growth factors released during inflammation and angiogenesis, such as
TGF-ii, stimulate ECM production by fibroblasts (119). Fibroblasts are also a source of
proteases (MMPs and uPA) (41) (Section 1.1.1.3), which are required for
angiogenesis (48) (Sections 1.1.3.1 and 1.1.3.2). In certain tumours, such as breast
carcinoma and colon adenocarcinoma, fibroblasts are a major source of MMPs (41, 120).
1.1.2.5 Non -cellular components of the ECM
The non-cellular components of the ECM are ground substance (glycosaminoglycans and
extracellular fluid), fibres (collagen and elastin) and glycoproteins (fibronectin, fibrillin,
laminin, entastin, tenascin) (109). The concentration, structure and arrangement of the
various components affects the mechanical forces imposed on cells (by the ECM), cell
morphology and consequently cell activities (45, 121). Ingber (1990) demonstrated that
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increased concentrations of fibronectin exert forces that increase endothelial cell
spreading/extension and that this change in morphology leads to increased endothelial cell
proliferation (122). Similarly, forces imposed on endothelial cells by the fibrin ECM
component induce capillary tube formation via influencing cell morphology (123). It
appears that the ECM influences cell cycle and cell survival-related molecules by spatial
organisation of cells within tissues (45, 124). Thus, changes in ECM fibre/glycoprotein
arrangement could alter cell behaviour. ECM fibres may also contribute to angiogenesis and
tumourigenesis through their chemotactic activity. Fibrin is chemotactic for inflammatory
cells and also provides a supporting network for the migration of these cells (Section
1.1.1.3), as well as endothelial cells.
Modification of the ECM structure by proteolysis modulates the exposure of different
domains that regulate cell behaviour (121). For example, proteolysis of collagen 1 exposes
integrin binding sites and thereby regulates cell adhesion and
migration (125) (Section 1.1.2.6). Fragments of ECM that are produced by proteolytic
cleavage can influence angiogenesis and tumourigenesis (121). For example, endostatin is
an ECM fragment that inhibits angiogenesis (Table 1.1) and laminin-5 fragments (found in
tumours) enhance the motility of breast epithelial cells (126).
The ECM can also regulate cell function by acting as a ligand for adhesion molecules, such
as integrins. Integrin signalling can regulate various aspects of cell behaviour that impact on
angiogenesis and tumourigenesis (25) (Section 1.1.2.6). The ECM can act as a regulator of
angiogenesis and tumourigenesis via modulation of growth factor availability and activity.
Several angiogenic growth factors are sequestered in the ECM. For example, bFGF is bound
to heparan sulfate (127). Other sequestered growth factors include latent TGF-13 (47) and
some isoforms of VEGF (128). The factor IGFBP-5 may be ECM-bound, and as bound and
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free IGFBP-5 have different affinities for IGF, this allows for regulation of IGF
availability (129). The interaction of the ECM with adhesion receptors can increase the
efficacy of growth factor signalling (130) (Section 1.1.2.6).
1.1.2.6 Cell adhesion
1.1.2.6.1 Cell adhesion and motility
Modulation of cell-ECM and cell-cell contacts is essential for the migration and invasion of
endothelial cells during angiogenesis (131) and invasion of tumour cells (Section 1.1.1.3). It
appears that co-coordinated detachment and reattachment at both ends of cells are required
for movement (132). Reorganisation of the cytoskeleton, which is modulated by adhesion
molecules (25) (Table 1.2), is necessary for the mobility of cells (132, 133). Restricted
pericellular proteolysis, in which cell adhesions play a role (Table 1.2), is required to remove
the ECM barrier to invasion while still preserving a supportive matrix for
migration (28, 134). In summary, controlled and balanced cell-ECM adhesion and
proteolysis are essential for movement i.e. opposite extremes of these processes inhibit
movement (135). Cell-cell contacts important for angiogenesis include those between
endothelial cells and pericytes. Upon the initiation of angiogenesis these contacts need to be
broken (and similarly tumour cells need to dissociate from the tumour for
invasion, Section 1.1.1.3) before penetration of the basement membrane (68). With capillary
tube formation, endothelial-pericyte contacts need to be re-established for normal vascular
morphogenesis and to inhibit endothelial cell proliferation (136)
1.1.2.6.2 Cell adhesion molecules
The four families of cell adhesion molecules include integrins, cadherins, selectins and
immunoglobulin (Ig) superfamily members (131). Their function and role in angiogenesis is
summarised in Table 1.2.
22
Table 1.2 The role of CAMs in angiogenesis
CAM
.
Function and role in angiogenesis References
Integrins • Heterodimeric transmembrane proteins with over twenty (22)
combinations of fifteen a and eight 13 subunits. (25)
• Present in cellular focal adhesion sites that make contact with the ( 131 )
ECM. (137)
• Main molecules responsible for ECM-cell adhesion. (138)
• Integrin signalling results in FAK phosphorylation which results in (139)
recruitment of focal adhesion proteins, formation of focal adhesion (140)
complexes and stabilisation of adhesion. (141)
• Integrin signalling involves RhoGTPase activation which also (142)
promotes adhesion and modulates the cytoskeleton, affecting (143)
motility. (144)
• Growth factors signal dephosphorylation of FAK, which promotes (145)
cell detachment from the ECM. However, growth factors also cause (14 6 )
activation of RhoGTPases that activate integrin signalling and
promote cell adhesion.
(147)
• When ligand-bound, increase the effectiveness of growth factor
signalling.
• Activation of MAPK by integrins may promote growth.
• Signal cell survival by upregulation of anti-apoptotic proteins or
downregulation of pro-apoptotic pathways.
• Integrin a v f3 3 (which is highly upregulated on activated endothelium
and virtually absent from quiescent endothelium) is required for the
survival of activated endothelial cells.
• Integrin a,13 3 	binds MMP-2, allowing for restricted pericellular
proteolysis during angiogenesis.
• Participate in capillary tube formation.
• Integrin inhibitors inhibit angiogenesis and tumour growth.
Cadherins • Transmembrane polypeptides that form the cell-cell contacts of (14)
adherens junctions. (131)
• Angiogenic growth factors phosphorylate and thereby loosen VE-
cadherin contacts, resulting in :
• increased vascular permeability
• endothelial cell detachment from neighbouring cells
• endothelial cell proliferation
• Re-formation of VE-cadherin adhesions is necessary for vascular
morphogenesis.
• Important regulators of tumour invasiveness (section 1.1.1.2).
Selectins • Endothelial membrane glycoprotein. (131)
• Promotes leucocyte adhesion to endothelium. (148)
• Blocking of E-selectin inhibits capillary tube formation in vitro. (149)
• Blocking of E-selectin inhibits angiogenesis in vivo.
lg • Mediate heterotypic cell-cell adhesion. (68)
superfami I y • Include the leucocyte adhesion molecules, ICAM-1 and VCAM-1. (149)
members • ICAM-1 and VCAM-1 are upregulated during angiogenesis.
• VCAM-1 can induce angiogenesis in vivo.
CAM - cell adhesion molecule; ECM - extracellular matrix; FAK - focal adhesion kinase; RhoGTPases - the Rho family of
guanine triphosphatases; MAPK - mitogen activated kinase; MMP-2 — matrix metalloproteinase-2; 1g - immunoglobulin;
ICAM-1 - intercellular adhesion molecule-I; VCAM-1 - vascular cell adhesion molecule-I
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1.1.3 Protease systems, cancer and angiogenesis
1.1.3.1 Plasminogen activation system
The plasminogen activation system includes urokinase/tissue plasminogen activator
(uPA/tPA), plasmin, uPA receptor (uPAR), annexin II (tPA receptor) and plasminogen
activator inhibitors (PAIs) (150). Both uPA and tPA cleave plasminogen to produce
plasmin. Tissue PA is primarily involved in intravascular plasmin generation for fibrinolysis
of blood clots. This is promoted by the binding of tPA to annexin II. The uPA system
functions extravascularly, where it is expressed by cell types such as macrophages and
fibroblasts, and is therefore more relevant to tumourigenesis and angiogenesis (20).
The factor uPA is a serine protease that is secreted as a single chain proenzyme
(scuPA) (31). The scuPA binds to uPAR (151), where it may be converted to uPA by
proteases (152). Plasmin cleaves ECM components such as fibrin, fibronectin, laminin and
proteoglycans (153), proMMPs (including MMP-2 and MMP-9) (154), cell adhesion
molecules (20), and growth factors, for example, cleavage of VEGF to bioactive
forms (155). Plasmin-mediated proteolysis results in the release of growth factors
sequestered in the matrix, including bFGF (127). While the uPA system promotes growth
factor activity, growth factors upregulate uPA and uPAR (153, 156). In addition to plasmin
generation, uPA mediates its effects via modulation of uPAR adhesion to vitronectin and
also signalling that results from its binding to uPAR (150, 157). This signalling affects cell
adhesion, motility and growth (31). The PAls control the activity of uPA. Both PAI - 1 and
PAI-2 bind to uPA, thereby inhibiting its plasminogen cleaving activity (31, 158). In
addition, PAI-1 displaces uPAR from vitronectin (150, 159). The uPA system may promote
either fibrinolytic or adhesive activity (in fact, both states may possibly occur at different
regions on the same cell) and co-ordinate this to allow the sequential attachment and
detachment required for movement (150, 152) (Section 1.1.2.6.1). This is achieved by
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regulation of uPAR-vitronectin adhesion by uPA, plasmin and PAI-I and by interactions of
uPAR with integrins following uPA binding (20, 150, 160).
1.1.3.2 Matrix metalloproteinases (MMPs)
The first MMP, collagenase or MMP-I, was isolated in 1962 by Gross and Lapiere from a
tadpole tail and 19 others have since then been identified (19). Matrix metalloproteinases
are secreted by macrophages, endothelial cells and fibroblasts in a proform that is activated
proteolytically by serine proteases, such as plasmin, and MMPs are
self-proteolytic (19, 161). They are inhibited by tissue inhibitors of MMPs (TIMPs). Matrix
metalloproteinase levels are low in normal adult tissues and only become elevated during
conditions of tissue remodelling, including wound healing, tumourigenesis and
angiogenesis (19). However, the induction of arthralgia by MMP inhibitors implies a role
for MMPs in normal joint function (19). Elevation of MMPs during conditions involving
tissue remodelling is as a result MMP expression induced by growth factors that arc
upregulated in these conditions (68), for example VEGF (162). The MMPs promote cell
migration via ECM proteolysis, e.g. via restricted fibrinolysis (28). Collectively, MMPs
degrade all ECM components (163). Alteration of ECM composition and structure via
proteolysis also affects cell migration and other behaviours (adhesion and growth; Section
1.1.2.5). Specifically, MMP-2 cleavage of the laminin-5y2 chain causes release of a
fragment that may bind to malignant breast epithelial cell receptors and induce migration
(Section 1.1.2.5), possibly via integrin-mediated signalling that modulates the cytoskeleton
(164). Furthermore, MMPs cleave cell adhesions mediated by E-cadherin and integrins,
thereby affecting cell migration (18, 165). The MMPs regulate cell growth by releasing
growth factors sequestered in the matrix (19, 166), cleaving IGFBPs (167), processing
growth factors into active forms (168) and via cleavage of growth factor receptors, such as
25
FGFRI (169). Refer to Table 1.3 for the role of MMPs and the uPA system in cancer and
angiogenesis.
1.1.3.3 The kallikrein-kinin system (KKS)
The KKS is a protein system that is involved with certain angiogenic and tumourigenic
factors that were discussed in Sections 1.1.1 and 1.1.2 and represented in
Figures 1.1 and 1.2. This involvement is represented in Table 1.4, which is presented at the
end of Section 1.1.3.3, page 45. The KKS consists of kallikreins, kininogen, kinins,
kininases and kinin receptors. Kallikreins are a family of serine proteases, some of which
have the ability to cleave kininogen to produce kinins, vasoactive peptides. Kinins exert
their effects through two G-coupled receptors viz. bradykinin receptor subtype 1 (I31R) and
bradykinin receptor subtype 2 (B2R), and are metabolised by kininases. A diagrammatic
overview of the KKS is presented at the end of Section 1.1.3.3, page 44.
1.1.3.3.1 Overview of the KKS components
1.1.3.3.1.1 Kallikreins
In 1909, Abelous and Bardier discovered the presence of a hypotension-inducing substance,
which they named urohypotensine, in human urine (170). This substance was subsequently
isolated and characterised by Frey and Kraut in 1928 (170). Since high levels of this
substance were found in the pancreas, Werle and colleagues introduced the term `kallikrein',
derived from the Greek word for pancreas, `kallikreas' (170). Subsequently, a distinction
was made between plasma kallikrein (PK) and the tissue kallikrein (TK) multigene
family (171). The gene for "true" TK or hKl, KLK1, was discovered in 1985, followed
closely by the discovery of KLK2 and KLK3, which code for proteins hK2 and hK3,
respectively (172). During the period 1994-2001, 12 additional KLKs (coding for hK4 to
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Table 1.3 The role of the uPA system and MMPs in cancer and angiogenesis.
Protease Role in cancer and angiogenesis References
uPA system • Involved in endothelial cell penetration of vascular basement (3/)
membrane. (68)
• Promotes endothelial cell invasion of the surrounding ECM. (157)
• Endothelial migration induced by bFGF and VEGF is dependent on (173)
the binding of uPA to uPAR. (174)
• Plasmin releases ECM-bound growth factors with angiogenic and (175)
tumourigenic activity. (176)
• uPAR is involved in mitogenic signalling. (177)
• Upregulated in tumours.
• Modulation of macrophage migration may contribute to increased
macrophages in tumours.
• Promotes motility in LnCAP cells (prostate tumour cells), human
glioma cells and breast cancer cells.
• Promotes metastasis in rat breast tumours, murine B16 melanomas,
human melanomas, uveal melanomas and human prostate
carcinomas.
• PAls limit excessive proteolysis (excessive proteolysis is
detrimental to angiogenesis (section 1.1.2.6.1)).
• Generates angiostatin, an anti-angiogenic factor that inhibits the
growth of metastases (Table 1.1), from plasminogen.
MMPs • MMP inhibitors inhibit angiogenesis in vitro and in vivo. (68)
• Involved in endothelial cell penetration of vascular basement (146)
membrane. (178)
• MMP-2 binds to cx.,13 3 	on angiogenic endothelial cells and (179)
melanoma cells, which allows for localised degradation of the (180)
ECM as these cells migrate. (181)
• MMPs (expressed by endothelial cells) are important for capillary (182)
tube formation. (183)
• Upregulate growth factors with pro-angiogenic or tumourigenic (184)
activity. (185)
• Have been positively correlated with tumour progression and
tumour aggressiveness in several tumour types (68).
• MMP correlation with metastasis is not consistent for lung
tumours.
• Cleave transglutaminase, an adhesion receptor, at the leading edge
of migrating cancer cells, positively contributing to their migration
on collagen.
• Membrane-type 1 MMP cleaves CD44 (frequently expressed by
tumour cells), thereby stimulating tumour motility.
• High levels of TIMPs are associated with a poor prognosis, as this
may inhibit excessive proteolysis.
• Generates angiostatin, an anti-angiogenic factor that inhibits the
growth of metastases (Table 1.1), from plasminogen.
uPA system - urokinase plasminogen activation system; ECM - extracellular matrix; bFGF - basic fibroblast growth factor;
VEGF - vascular endothelial growth factor; uPA - urokinase plasminogen activator; uPAR - receptor for urokinase
plasminogen activator; PAI - inhibitor of plasminogen activator; MMP — matrix metalloproteinase; TIMP - tissue inhibitor
of matrix metalloproteinases
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hK15) were identified (172). The present project focused only on "true" TK. In the
literature and in the present project the term TK is used to refer to "true" TK protein. For the
purpose of distinguishing TK from other tissue kallikreins, the remaining 14 members of the
tissue kallikrein family will be referred to as kallikreins. The location, gene/protein structure
and regulation of TK follows.
1.1.3.3.1.1.1 Location of TK
Tissue kallikrein is found in the pancreas, salivary glands, kidneys, intestine, sweat glands,
adrenals, spleen, reproductive tissues, plasma (186), neutrophils (187), macrophages (188)
and endothelial cells (189).
1.1.3.3.1.1.2 Gene and protein structure of TK
The KLKI gene is clustered together with the other 14 kallikrein genes on chromosome
q13.3-13.4. (170, 190). All kallikrein genes have 5 coding exons of similar size (170). The
second, third and fifth coding exons code for histidine, aspartate and serine residues,
respectively, that belong to the catalytic triad of all kallikreins (170, 171, 191). Kallikreins
have a 30-50% amino acid homology with the exception of hK2 and hK3, which have 80%
homology (170). All proteins are translated as preproenzymes that contain a signal peptide
(16-30 amino acids) at the amino terminus (170, 172, 192). Cleavage of the signal peptide
results in the formation of proenzymes that are subsequently secreted (170, 172, 192).
Further removal of a propeptide of 4-9 amino acids results in a fully active, mature enzyme,
a single chain glycoprotein (170, 172, 192).
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1.1.3.3.1.1.3 Regulation of TK
1.1.3.3.1.1.3.1 Transcriptional regulation of kallikrein genes: steroid hormones
All kallikrein genes are under direct and indirect transcriptional regulation by steroid
hormones. Most are upregulated by androgens, oestrogen and progestin, although to
differing extents (170). This is the major mechanism of transcriptional control (172). Direct
hormonal control involves the binding of activated steroid hormone receptors to steroid
hormone response elements (REs) in the promoter regions of genes, followed by recruitment
of transcriptional machinery (172). Functional androgen REs (AREs) have been identified
in the promoter/enhancer regions of KLK genes 2 (193) and 3 (194). AREs have also been
identified in KLK4, 14 and 15 (172) and an oestrogen response element (ORE) in KLKI
(195), although they have not yet been functionally tested (172). Steroid hormone receptors
may also interact with transcription factors rather than binding to genes directly, thereby
indirectly influencing transcription (172). Other indirect mechanisms of transcriptional
regulation may occur via signalling pathways that crosstalk with steroid hormone response
pathways (196). For example, growth factor signalling pathways modulate the activity of
co-regulators of steroid hormone receptors (197) (Section 1.1.3.3.2.6.2).
1.1.3.3.1.1.3.2 Post-transcriptional regulation of TK activity
Pro-kallikreins require proteolysis for activation. Takada et al. (1985) demonstrated that
human urinary prokallikrein (i.e. proTK) could be activated by serine proteases such as
trypsin and PK, and also by the metalloproteinase thermolysin (198). Serine proteases, such
as plasmin, can activate pro-kallikreins (199). Further, kallikreins may have autocatalytic
activity or activate one another (172, 191, 200, 201). This suggests the possibility that
kallikreins become activated in a proteolytic cascade-like manner, as serine proteases of the
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clotting pathway (191). Supporting this hypothesis is the co-expression of many kallikreins
in the same tissue and hormonal regulation of all kallikreins (191).
Proteolysis of kallikreins may also be a mechanism of inactivation. Some kallikreins, such
as hK6 and 13 have the ability for autoinactivation (172). Serine protease inhibitors
(serpins) may post-translationally inactivate TK via the formation of a serpin-protease
complex. Serpins include kallistatin (first observed to bind to TK; (202)), al -antitrypsin,
PAl-I and antithrombin III, for example (135).
1.1.3.3.1.2 Kininogen, kinins and kininases
In the late 1930s, Werle and colleagues found that the hypotensive and gut smooth muscle-
contracting effects of kallikrein were not due to kallikrein itself, but rather as a result of a
biologically active molecule released by kallikrein-mediated cleavage of its precursor
(kininogen) (171). This molecule was initially named kallidin by Werle and Berek.
Subsequently, Roche e Silva and colleagues identified a substance with activity similar to
that of kallidin, which they named bradykinin (BK) (171). This name is Greek -derived from
its slow (`brady') muscle contracting (`kinin" means movement) action. By the end of the
1960s, the structure of BK and several functionally similar molecules, collectively called
kinins, had been solved and their biological effects tested (203) (Section 1.1.3.3.2.2). At
approximately the same time, kininogens became classified as high and low molecular
weight kininogen, HMWK and LMWK, respectively (171). Plasma kallikrein and TK
cleave HMWK and LMWK differentially to release different kinins. PK cleaves HMWK at
lys-arg and arg-ser bonds, releasing the nonapeptide, BK (171). Plasma kallikrein may also
release BK from LMWK that has been cleaved by neutrophil elastase, although this is a poor
substrate for PK (204). Tissue kallikrein cleaves the met-lys bond as well as the arg-ser
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bond of LMWK to produce kallidin (lys-BK) (171, 192). This is the generally accepted
kininogen-cleaving activity of TK, but it has also been shown to readily produce kinins
(bradykinin and kallidin) from HMWK in vitro (171, 205-207). Discovery of the kininases,
the enzymes that cleave kinins, also began in the 1960s. Kininase family 1 carboxypeptidase
N and M (KI-CPN and KI-CPM) remove the carboxy terminal from kinins, resulting in the
release of biologically active des-arg 9-BK and des-arg 9-lys-BK (171, 208). Kininase family
II angiotensin I-converting enzyme and neutral endopeptidase (Kul-ACE and KII-NEP)
further degrade these kinin derivatives, inactivating them (171, 209). Aminopeptidase is a
kininasc that can convert kallidin to BK (192).
1.1.3.3.1.2.1 Location, structure and regulation
A single human gene, consisting of 11 exons and 27 000 base pairs, encodes kininogen. The
HMWK (88-120 kDa) and LMWK (50-68 kDa), single chain glycoproteins, are then
produced by alternate splicing (171, 192). The primary structures of kininogens, as well as
kinins, are represented in Figure 1.3, which is presented at the end of Section 1.1.3.3.
Kininogens are synthesised by several cell types viz. hepatocytes, platelets, acinar cells of the
submandibular gland, human kidney, endothelial cells and neutrophils (171). High
molecular weight kininogen circulates in the blood stream bound to pre-PK, although this
complex is also found bound to the surface of the neutrophil (171, 210). LMWK may be
found in plasma (211), bound to the surface of neutrophils (210) or localised in the various
tissues mentioned above (171).
Generation of kinins occurs when TK and PK become activated and come into contact with
kininogens. Plasma kallikrein is activated by blood vessel damage (212) and TK is activated
by proteases (Section 1.1.3.3.1.1.3.2), which may be released during tissue damage or
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inflammation (213). Kinins are not exclusively formed by kallikrein action. Snake venom
proteases, trypsin and plasmin are also capable of releasing kinins (171). Mast cell tryptase
and neutrophil elastase, released during inflammation, may act in concert to release BK from
kininogen substrate (207). This activity may be important in an oxidative environment, such
as during inflammation, as oxidation of the methionine residue of kininogen affects
kallikrein-mediated kininogen processing. However it does not affect the kininogenase
activity of tryptase/elastase. Refer to Section 1.1.3.3.2.2 for biological effects of kinins.
The half-life of kinins is less than 30 seconds due to their rapid degradation by kininases,
and this allows for acute regulation of their activity (214). Kininase family I
carboxypeptidase N is synthesised in the liver and is present in plasma associated with
endothelial cells (171). Kininase family I carboxypeptidase M is located in plasma
membranes in human kidney, lung, fibroblasts, pulmonary artery endothelial cells and
placenta (171). Kininase family II angiotensin I-converting enzyme resides in the
endothelial plasma membranes in the lung from where it is primarily responsible for
inactivation of kinins (214). Kininase family II neutral endopeptidase is localised on
membranes (209), or secreted into biological fluids (171). An important function of KII-
NEP may be to regulate activity of kinins formed on the neutrophil surface as it is found on
the surface of neutrophils (171). Aminopeptidase P is present in the red blood cells, kidney
and lung (171).
1.1.3.3.1.3 Kinin receptors
In 1977, Regoli and colleagues presented the first evidence to suggest the existence of two
kinin receptor types (215). These investigators demonstrated a greater potency of des-arg 9-
BK than BK in a rabbit aorta preparation, which contrasted with the typical order of agonist
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potency (BK > lys-BK > des-arg 9-BK) in classical preparations (such as rat uterus) (171,
215, 216). Further, antagonists based on the structure of des-arg 9-BK were demonstrated to
have little effect on classical preparations (216). In 1980, Regoli and Barabe proposed that
kinin receptors be divided into two types based on the order of agonist potency and the
affinity of antagonists (215). Those receptors activated most strongly by kinins without the
carboxyl arginine, significantly activated by kallidin and responsive to des-arg 9-BK
antagonists were named B1R (lys-des-arg
9
-BK > lys-BK > des-arg
9
-BK > BK), whereas
those little affected by these kinin derivatives and antagonists were named B2R (BK > lys-
BK > des-arg9-BK > lys-des-arg9-BK) (203, 215). This classification became firmly
established with the development of B2R antagonists based on the structure of BK (217). By
the late 1980s, several intracellular signalling routes following activation of the kinin
receptors had been outlined (203). In the late 1990s, advances were made in the
identification of the roles of the kinin receptors in disease and non-peptide receptor
antagonists, with the potential to treat these diseases, were developed (203). More recently,
direct activation (independent of kinin generation) of the B2R by TK and other serine
proteases was reported (218), however a subsequent study failed to support those
findings (219).
1.1.3.3.1.3.1 Gene and protein structure
The B2R gene is located 5' relative to the BIR, separated by 12 000 base pairs, on
chromosome 14832 (220). Both genes have three exons and are 36% homologous (203).
Both receptors span the membrane seven times, have three extracellular loops with three
consensus sites for N-linked glycosylation and three intracellular loops, possess DRY and
NPXXY motifs and putative phosphorylation and acylation sites (172, 221). The main
difference between the two receptors is the C-terminal tail. The B2R has a longer C-terminal
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tail than the B I R with clusters of serine and threonine residues, that may be phosphorylated,
and cysteine residues, that may be acetylated (203).
1.1.3.3.1.3.2 Regulation of receptor expression and activity
Both B I R and B2R may be expressed by vascular cells, nonvascular smooth muscle cells,
fibroblasts, epithelial cells and cells of the nervous system. However, the expression of B I R
is only induced in pathological conditions, whereas B2R is present physiologically (203).
The B I R is induced by noxious agents probably as a result of the inflammatory response to
these agents (203). Inflammatory cytokines, such as interleukin 1 (IL- 1), and growth factors,
such as EGF, induce B1R expression (222). Glucocorticoids have an inhibitory effect on
B 1R expression (222). These effects appear to be linked to the presence of a NE-K(3 (nuclear
factor of the K-enhancer in B cells) motif in the promoter region of the B1R gene (223, 224).
Cytokines and inflammatory mediators may induce B1R expression through activation of the
transcription factor NF-K43 (203). Glucocorticoids upregulate laf3a, a factor that inhibits
NF-K13 (203).
The transcription of B2R is also increased by inflammatory cytokines and growth
factors (225). Some regulatory elements in the B2R gene promoter include binding sites for
IL -6 activator protein, cAMP (cyclic adenosine monophosphate)-response element binding
protein, NF-K(3, glucocorticoid, intestinal natriuretic factor and oestrogen (203). Therefore,
TK as well as B2R may be hormonally regulated. Another mechanism of increased B2R and
B1R is IL-1-mediated stabilisation of B2R/B1R mRNA (messenger ribonucleic acid) (226).
However, while B2R activity is downregulated and desensitised in response to BK
exposure (227, 228) and may sometimes be downregulated during intense, chronic
inflammation (203), BI R remains constitutively active (203, 229). This may be largely due
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to the lack of phosphorylation sites in the B IR C-terminal tail when compared to that of the
B2R (230) (Section 1.1.3.3.1.3.1). When BK binds to B2R, phosphorylation of threonine
and serine residues occurs and this promotes receptor desensitisation (228) and
internalisation (231). Supporting this is the very limited capability of B1R for
desensitisation (229) and internalisation in response to agonist exposure (230). The main
difference between B1R and B2R signalling is the significant sustainment of B1R signalling
in comparison to B2R signalling (229).
There are many other negative feedback pathways induced by BK binding to B2R, including
G protein-caveolae associations (232) and decreased G protein activation (203, 233).
Additionally, external factors such as increased proteases in chronic inflammatory conditions
may inactivate the B2R by cleavage (203).
1.1.3.3.1.3.3 Receptor signalling pathways
The signalling pathways of B1R and B2R, which are initiated by ligand binding, are very
similar (203). Kinin signalling involves receptor interaction with different types of G
proteins (234), phosphoinositol hydrolysis by phospholipase C ((235) (hydrolysis initiated
by BK may also be mediated by kinin-mediated phosphoinositide 3-kinase (PI3K)
activation (236)), increased intracellular calcium concentration (235), nitric oxide synthase
(NOS) activation (237) (resulting in NO production), eicosanoid production (238) and
mitogen activated kinase (MAPK) activation (239). Activation of MAPK, following B2R
stimulation, is protein kinase C (PKC) dependent and involves activation of tyrosine
kinases (240). Stimulation of B2R also results in activation of RhoGTPases (Rho guanine
triphosphatases), focal adhesion kinase (FAK) and several transcription factors (NF-x(), that
induce transcription of cytokines (203).
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1.1.3.3.2 Physiology and pathophysiology of the KKS
1.1.3.3.2.1 Biological effects of TK
Tissue kallikrein has been implicated in the processing of several growth factors and
hormones. Jones et al. (1992) reviewed the possible role of TK in the processing of
prolactin in the pituitary before its secretion (186). Tissue kallikrein is thought to be
involved in the turnover of nerve growth factors and hormones that are essential for
neurotransmission and normal nerve function (213). The proteins processed by TK include
pro-insulin, low density lipoprotein, precursor of atrial natriuretic prorenin, vasoactive
intestinal peptide and angiotensinogen (171, 192). Other kallikreins are implicated in the
processing of growth factor and peptide hormones, particularly in the pancreas and nervous
system (1 72).
A study by Wolf and colleagues (2001) suggested the involvement of TK in ECM
cleavage (241). In that study, an inhibitor of TK, FE999024, reduced invasion of matrigel
by breast tumour cells and pulmonary extravasation in an ex vivo rat model. Whether this
was directly mediated by TK is unclear. Other kallikreins, namely hK2, 3, 5, 13. and 14, are
capable of directly cleaving the ECM (172) and 13Orgono et al. (2004) suggest that they may
play a role in tissue remodelling comparable to MMPs (I 7 2). However, only indirect
mediation of proteolysis (through upregulation of other proteases) has been clearly
demonstrated for TK. Tissue kallikrein has the ability to activate the proteases
MMP-2 (242) and MMP-9 (243). Activation of PAR-1, leading to MMP-12 secretion (244),
may be another mechanism of TK-mediated increase in MMP activity. Tissue kallikrein has
not been demonstrated to activate the plasmin system. However, hk4 has the ability to
cleave uPAR, as well directly cleaving and activating uPA (245). Proteolysis of the ECM
affects cell adhesion and motility (Section 1.1.2.5). thereby implicating an indirect role of
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TK in these processes. Despite the many proteolytic-mediated effects of TK, generation of
kinins is considered to be its primary function (1 70, 172).
1.1.3.3.2.2 Biological effects of kinins, as mediated by B1R and B2R
1.1.3.3.2.2.1 Vasoactivity
Prostacycl in and NO, which are produced as a result of B 1 R/B2 R
signalling (Section 1.1.3.3.1.3.3), act on smooth muscle cells to induce vasodilation (203).
Rho G protein that is activated by B2R signalling breaks down endothelial intercellular
junctions, thereby separating endothelial cells and increasing vascular
permeability (246) (Section I .1.3.3.1.3.3). The vasoactivity of kinins has been implicated in
the control of renal blood flow and regulation of blood pressure (171).
1.1.3.3.2.2.2 Promotion of growth
1.1.3.3.2.2.2.1 NO and tyrosine kinases
Kinin receptor signalling (Section 1.1.3.3.1.3.3) produces NO, which potentiates tyrosine
kinase receptor signalling (247). Several reactive nitrogen intermediates (RNIs) may be
derived from NO, including peroxynitrite (ON00) (247, 248). Reduction of ON00 - to
form peroxynitrous acid (ONOOH), followed by its decomposition produces hydroxyl
radicals (011), which are highly oxidative reactive oxygen intermediates (ROIs). Both RN1s
and ROIs modulate signalling pathways (247). They can oxidise and thereby inactivate
tyrosine phosphatases, indirectly increasing tyrosine phosphorylation. This potentiates the
activation of tyrosine kinase receptors, which include the following growth factor receptors:
insulin, EGF, IGF, PDGF, VEGF and FGF. Reactive nitrogen intermediates and ROIs may
also stimulate tyrosine kinase dependent activation of MAPKs that are usually part of growth
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factor signalling pathways (247, 249) and also various transcription factors (through
oxidation of cysteine residues or iron-sulphur centres) (247).
1.1.3.3.2.2.2.2 VEGF
Hayashi et al. (2002) have demonstrated an increase in VEGF mRNA in rats following
injections of a BK agonist (250). Subsequently, BK was found to upregulate VEGF
production in stromal fibroblasts in mice and rats with sarcoma 180 and Walker tumours,
respectively (251, 252). Bradykinin was also shown to upregulate VEGF production in
vascular smooth muscle cells (253). This occurs via B2R activation followed by PKC
activation. Not only do kinins upregulate VEGF production but they also potentiate VEGF
signalling. Thuringer et al. (2001) demonstrated that activation of B2R by BK could
transactivate the VEGFR, Flk-1, in endothelial cells (249). Some NOS activation still
occurred when Flk-1 was inhibited. Therefore, the NO production due to kinin receptor
activation alone would potentiate that produced by Flk-1 activation. Similarly, Miura et al.
(2003) demonstrated transactivation of Flk-1 by B2R, followed by NOS activation, in
coronary endothelial cells (254). Other overlaps in the signalling pathways of B1/2R and
Flk-1 are PI3K and MAPK activation (255) (Section 1.1.3.3.1.3.3).
1.1.3.3.2.2.2.3 bFGF
Bradykinin acts synergistically with bFGF to induce proliferation in coronary postcapillary
endothelial cells (256). In this instance, activation of the B 1 R was responsible for the effect
of BK. A mechanism by which BIR activation potentiates actions of bFGF was
demonstrated by Parenti et al. (2001) to be NOS-dependent upregulation of bFGF (257).
Another possible mechanism is the generation of MAPK by B I R activation as MAPKs are
involved in bFGF signalling (255).
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1.1.3.3.2.2.2.4 EGF
Epidermal growth factor is a mitogen that is found in many tissues (258). BK signalling
may result in the transactivation of the EGF receptor (EGFR) and in some cases, the actions
of BK may be dependent on this transactivation (259, 260). Epidermal growth factor
signalling involves activation of phospholipase C (261) and thus may be potentiated by
kinin-mediated phospholipase C activation (Section 1.1.3.3.1.3.3).
1.1.3.3.2.2.2.5 TGF- 13
BK may induce TGF-131 expression via a MAPK-dependent pathway in vascular smooth
muscle cells (262). Although TGF-13 is growth inhibitory in healthy epithelial tissue, it may
promote growth in pathological conditions (263) (Section 1.1.3.3.2.6.2).
1.1.3.3.2.2.2.6 Cytokine production
Kinin receptor activation results in upregulation of IL-1 production in fibroblasts and 11,-8
production in smooth muscle cells (203). Kinins may also stimulate the release of IL-1 and
TNF by macrophages (264).
1.1.3.3.2.2.2.7 Modulation of glucose metabolism
Kinins cause a hypoglycaemic effect (171). They improve the transport of glucose to tissues
via enhancement of blood flow and they increase tissue uptake of glucose. They may further
cause increased glucose oxidation in the presence of insulin, thereby providing energy for
growth (171).
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1.1.3.3.2.2.3 Modulation of cell adhesion and motility
The activity of RhoGTPases and FAK, which affect cell adhesion and motility, may be
modulated by kinin receptor activation (Sections 1.1.2.6 and 1.1.3.3.1.3.3). Production of
NO (which may occur via kinin receptor activation, Section 1.1.3.3.2.2.2.1) has been
demonstrated to promote endothelial cell migration by modulating the phosphorylation status
of FAK proteins and the assembly of stress fibres (133). Proteolysis of the ECM and cell
adhesions, indirectly mediated by kinins, impacts on cell motility (Sections 1.1.2.5 and
1.1.3.3.2.2.4).
1.1.3.3.2.2.4 Indirect proteolytic function
The RNI, ON00 -, derived from kinin receptor signalling, is capable of activating several
MMPs (248). BK stimulates tissue PA activator release into the circulation (265),
subsequently resulting in activated plasmin, which may in turn activate MMPs (Section
1.1.3.1). Growth factor signalling, that is enhanced by kinins (Section 1.1.3.3.2.2.2), may
upregulate protease systems (Sections 1.1.3.1 and 1.1.3.2).
1.1.3.3.2.3 The role of the KKS in inflammation
The KKS plays a key role in inflammation (171, 266): TK upregulates proteolysis (Section
1.1.3.3.2.1) and kinins induce vasodilation, increase vascular permeability, promote cell
proliferation and upregulate proteolytic activity (Section 1.1.3.3.2.2). Kinins also induce
chemotaxis of neutrophils and monocytes (118). This was demonstrated by the release of
the chemotactic factors 1L-8, GCSF, GMCSF, monocyte chemoattractant protein-1, and
TGF-3 by lung fibroblasts in response to BK stimulation. Further, kinins are important for
neutrophil diapedesis (mediated by vascular permeability) and their subsequent infiltration of
tissues (267). Kinins also contribute to leucocyte activation, and neutrophils and
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macrophages at the site of inflammation display increased sensitivity to kinins, which is due
to the upregulation of kinin receptors on these cells (268).
The KKS becomes activated as a result of inflammation in response to tissue damage,
infection and/or tumourigenic cells (Section 1.1.3.3.1.2.1). Neutrophils appear to be an
important source of kinins in inflammation (266) since they demonstrate
TK (Section 1.1.3.3.1.1.1), HMWK and LMWK (Section 1.1.3.3.1.2.1). Cleavage of the
neutrophil kininogen in inflammatory conditions (pneumonia, tuberculous meningitis and
rheumatoid arthritis) has been observed (266). Other inflammatory cells, namely human
macrophages and rat mast cells, possess KKS components, TK and kininogen,
respectively (269) (Sections 1.1.3.3.1.1.1 and 1.1.3.3.1.2.1). Neutrophil production of
cytokines may be largely responsible for the increased kinin receptor expression during
inflammation (203) (Section 1.1.3.3.1.3.2).
Evidence for the proinflammatory role of the KKS is provided by its involvement in chronic
inflammatory disorders, such as arthritis, asthma and inflammatory bowel disease (171).
There is evidence for increased TK secretion in inflammatory bowel disease, supporting
KKS involvement in this pathological state (188, 270). Kallistatin (a TK inhibitor) reduced
inflammation (and angiogenesis) in a rat arthritis model (108). Similarly, administration of
HMWK antibodies to Lewis rats with arthritis significantly decreased local and systemic
inflammation (271). The B1R has been implicated in allergic airway inflammation as
suggested by the inhibition of allergen-induced bronchial hypersensitivity in asthmatic rats
by B1R antagonists (203). A role for B2R in asthma is supported by the improvement of
forced expiratory volume achieved by B2R antagonists (203). There is also evidence for
KKS involvement in cancer (266) (Sections 1.1.3.3.2.4 and 1.1.3.3.2.6), another disease in
which there is chronic inflammation (Section 1.1.1.3).
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1.1.3.3.2.4 The KKS and cancer
Identification of TK and kinin receptors on the leading edge of neuroblastoma cells in an in
vitro model suggests that KKS-mediated proteolysis contributes to tumour invasion (2 7 2).
The inhibition of matrigel invasion by breast cancer cells due to a TK inhibitor. further
supports a role for the KKS in tumour invasiveness (Section 1.1.3.3.2.1). The expression of
TK has been demonstrated in human colon epithelial cancer (2 7 3), human endometrial
cancer (274), renal carcinoma (2 7 5) and pancreatic adenocarcinoma (2 4 1). Upregulation of
TK was observed in prolactin-secreting pituitary adenomas and growth-hormone-secreting
adenomas (186), gastric cancer (2 7 6) and oesophageal cancer (2 7 7). The remaining 14
members of the TK family are also implicated in tumourigenesis (1 7 2). They are either
upregulated or downregulated in cancers and may have either protective or tumourigenic
functions. They are also an important source of cancer biomarkers, particularly hK3 or
prostate specific antigen (PSA) (1 7 2). This antigen is expressed chiefly in prostatic tissue
and is generally elevated in the serum of prostate cancer patients, probably due to the
impaired integrity of the prostate gland ducts (278). Prostate specific antigen is also
expressed significantly in breast tissue and is a marker for breast cancer (I 7 0, 1 7 2). The role
of the KKS in prostate and breast cancer is dealt with further in Section 1.1.3.3.2.6.
Kinin generation has been identified in the ascitic fluid of tumours (2 7 9), with considerable
amounts of BK generated in ovarian carcinoma ascites (280). Kinins appear to be largely
responsible for the increased vascular permeability in ascitic tumours, which supports rapid
tumour growth (248, 2 7 9). Decreased plasma prekallikrein and kininogen levels in patients
with various types of cancers suggests that increased kinin generation occurs in cancer (2 8 I).
Further. BK antagonists show potent anticancer activity in lung and prostate cancers in vitro
and in murine models (refer to Section 1.1.4.2), as well as broad spectrum anticancer activity
against colon, cervical, pancreatic and breast cancers in vitro (2 8 2).
42
The presence of B2R has been identified in human endometrial cancer (274), and human
adenocarcinoma of the lung and stomach, lymphoma, hepatoma, squamous cell carcinoma of
the lung, carcinoid of the duodenum, as well as in several mouse tumours (283). The
presence of B1R and increased B2R have been observed in cervical cancer and
metastases (284) as well as in oesophageal cancer (277). Although B2R is absent in healthy
glial cells, it is expressed by astrocytoma (285).
1.1.3.3.2.5 The KKS and angiogenesis
There is abundant evidence that the KKS is involved in the angiogenic cascade (108, 254,
256, 286-294). Plendl et al. (2000) provided evidence that TK is involved in the angiogenic
cascade using an in vitro model of angiogenesis (286). In that study, increased intensity of
immuno-labelling for proTK was observed in microvascular endothelial cells as they
proliferated and migrated, eventually differentiating into tube-like structures. Comparatively
weak immuno-labelling was observed in non-angiogenic cells. Additionally, intense TK
immuno-labelling was observed in endothelial tubular structures and in the end of cellular
projections. Subsequently, Emanueli and colleagues (2001) showed that the angiogenic
response to ischaemia in a mouse model was enhanced by TK gene delivery (287) and that
TK gene delivery corrected impaired angiogenesis in spontaneously hypertensive TK
deficient rats (288). TK gene therapy also promoted angiogenesis in a cerebral ischaemic rat
model (289) and protected rats from ischaemic injury when administered after the onset of a
stroke (290). Recently, kallistatin (a TK inhibitor) was shown to inhibit angiogenesis (and
inflammation), subsequently leading to clinical improvement in arthritis rat models (108).
However, it is not clear whether this was due to the inhibition of TK because kallistatin has
also been shown to inhibit angiogenic activities induced by VEGF and bFGF (295).
Bradykinin was reported by Hu and Fan (1993) to potentiate IL-induced angiogenesis in
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vivo (291). In that study, Hu and Fan (1993) also showed that a B1R antagonist abolished
this effect. Subsequently, Emanueli and colleagues (2002) showed significant inhibition of
vessel growth in ischaemic muscle of a murine model by a B1R antagonist (292). These
authors suggested that this was due to B1R-mediated endothelial cell proliferation and
survival based on these observed effects in an in vitro experiment. Further, mitogenic
actions of kinins, mediated through the B1R, were shown to contribute to bovine coronary
endothelial cell proliferation (256). Subsequently, BK, via activation of B2R, was shown to
promote human coronary endothelial cell proliferation and tube formation in vitro (254).
Accordingly, HUVEC proliferation and cord formation in in vitro assays was inhibited by
BK antagonists (293). In a recent study, B2R activation promoted endothelial cell
proliferation in synovitis (294).
Several studies have implicated the KKS in tumour angiogenesis (250, 251, 272, 296).
Naidoo et al. (2004) found that immuno-reactive TK was reduced in HUVECs that were
challenged with neuroblastoma metabolites while release of TK into the medium was
increased (296). This indicated that neuroblastomas increase the secretion of TK by
endothelial cells possibly to facilitate tumour angiogenesis. The localisation of TK, I31R and
132R in co-cultures of neuroblastoma cells and HUVECs suggested a synergistic relationship
between angiogenic endothelial cells and tumour cells and that BIR and B2R may mediate
the invasion of endothelial cells at the leading edge in their movement towards
neuroblastoma cells (272). A role for BK in tumour angiogenesis was demonstrated by
suppression of tumour-associated angiogenesis in mice bearing sarcoma 180 cells by a B2R
antagonist (251). The suppression of tumour-associated angiogenesis in kininogen-deficient
rats and the reversal of this by a FR190997, a mimic of BK, further supports kinin




















Activation Kallikrein-kinin system (KKS) components
centromere 1
 I5 3 2 4 5 6 7 8 9 10 11 12 13 14 telomere






















































Table 1.4 Association of the activities of the KKS with tumourigenic/angiogenic factors.
Tumourigenic/angiogenic
factors
Activities of the KKS
1. GFs/cytokines • Kinin signalling potentiates that of GFs. Common signalling
intermediates: NO, MAPKs, P13K and PLC (1.1.3.3.2.2.2.1-5).
• Kinin signalling upregulates cytokine production (1.1.3.3.2.2.2.6).
• TK processes GFs and releases ECM-bound GFs (1.1.3.3.2.1).
• Kinins increase glucose metabolism, providing energy for growth
( 1.1.3.3.2.2.2.7)
• Kinins stimulate fibroblasts to release GFs and cytokines
(1.1.3.3.2.3).
2. ECM 2.1 fibres
(ECM
modification)
• Kinins induce vasodilation and increased vascular permeability
(1.1.3.3.2.2.1), which leads to extravascular clotting (1.1.1.3).
• TK may directly cleave the ECM (1.1.3.3.2.1).




• Kinins induce vasodilation and increased vascular permeability
(1.1.3.3.2.2.1), leading to an extravascular clotted matrix, which is
chemotactic for inflammatory cells (1.1.1.3).
• Kinins are important for neutrophil diapedesis (1.1.3.3.2.3).
• Kinins activate leucocytes (1.1.3.3.2.3).
• Kinins stimulate fibroblasts to release factors that are chemotactic
for inflammatory cells (1.1.3.3.2.3).
2.3 fibroblasts • Kinins stimulate fibroblasts to release GFs and cytokines (that are
chemotactic for inflammatory cells) (1.1.3.3.2.3).
2.4 blood vessels • The KKS is proinflammatory (1.1.3.3.2.3). Inflammation
promotes angiogenesis (1.1.2.4.1).
• Kinins and TK may promote angiogenesis by modulating the
activity of growth factors/cytokines, ECM components, cell
adhesion molecules and proteases — factors which direct
angiogenesis (1, 2, 3, 4 of this table, 1.1.2.2, Figure 1.2).
Angiogenesis promotes tumourigenesis (1.1.2.1).
3. Cell adhesion molecules • TK activates MMPs (1.1.3.3.2.1), which have the ability to cleave
cell adhesion molecules (1.1.3.2).
• Kinins potentiate GF signalling, which may lead to FAK
dephosphorylation, resulting in destabilisation of cell adhesion (1
of this table, 1.1.2.6).
• Kinins may potentiate integrin signalling, which affects cell
adhesion, motility, survival and proliferation. Common signalling
pathways: activation of RhoGTPases and phosphorylation of
FAK (1.1.2.6, 1.1.3.3.2.2.3).
4. Proteases • TK cleaves and activates MMP-2 and MMP-9 (1.1.3.3.2.1).
• TK may participate in a cascade-like activation of TKs, and some
of these TKs have the ability to activate uPA and uPAR
(1.1.3.3.2.1).
Numbers in brackets refer to sections of chapter 1.
KKS — kallikrein-kinin system; GF — growth factor; NO — nitric oxide; MAPK — mitogen activated kinase; PI3K —
phosphoinositide 3-kinase; PLC — phospholipase C; ECM — extracellular matrix; TK — tissue kallikrein; MMP — matrix
metalloproteinase; FAK — focal adhesion kinase, uPA — urokinase plasminogen activator; uPAR — receptor for urokinase
plasminogen activator
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1.1.3.3.2.6 The KKS in prostate and breast cancer
Prostate and breast tumours are the tumour types investigated in this project. The KKS may
be linked to the development and progression of these cancers.
1.1.3.3.2.6.1 Introduction to prostate and breast cancer
Prostate cancer is the most common cancer and second leading cause of death in men of
Western society (49, 297, 298). Similarly, breast cancer is the most common cancer in
women of Western society and accounts for approximately 18% of female deaths in these
countries (298 -300). Androgens and oestrogens drive the growth of prostate and breast cells,
respectively (49, 300, 301). Thus androgen ablation/anti-oestrogen treatments are the first
treatment choices for metastatic prostate/breast cancer, in which other treatment options are
ineffective (49, 299). However, in both prostate and breast cancer there is an inevitable
progression of the disease to an androgen independent (AI) and oestogen independent (01)
state, respectively (49, 302). Once prostate/breast cancer has become A1/01. prognosis is
poor and treatment is palliative (49, 299, 300, 303). Mechanisms of AUOI development
include enhanced receptor (AR/OR) expression, increased AR/OR sensitivity, AR/OR
sensitivity to ligands other than androgen/oestrogen, and ligand independent activation of
AR/OR involving co-regulator modulation and upregulation of growth factor
pathways (49, 197, 302, 304).
1.1.3.3.2.6.2 The role of the KKS in prostate/breast tumourigenesis and AI/01
Several growth factors, namely EGF, transforming growth factor alpha (TGF-a; a ligand of
EGFR), IGF, TGF-13, bFGF and VEGF have been implicated in the development of prostate
and breast cancer and their progression to Al and 01, respectively (Table 1.5). The KKS
potentiates the signalling of these growth factors (Section 1.1.3.3.2.2.2), thereby suggesting
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possible KKS involvement in prostate/breast tumourigenesis and the development of AI/01.
Growth factors increase the activity of the AR (Table 1.5) through the initiation of AR
phosphorylation or via phosphorylation of its co-regulators (197). Phosphorylation occurs
either via protein kinase B or MAPK (322). Kinin signal transduction also involves
activation of MAPK (Section 1.1.3.3.1.3.3) and therefore may positively influence AR
activity by this mechanism. Similarly, growth factors activate the OR independently of
oestrogen (Table 1.5) through phosphorylation of the AF-1 subunit of OR by MAPK
induction, which may be potentiated by kinin signalling (Section 1.1.3.3.1.3.3). The
phosphorylation of AF-1 enhances interaction of the OR with its coactivators, thereby
allowing OR activation (302, 312).
The KKS can be linked to Al prostate cancer and 01 breast cancer by factors other than its
interaction with growth factors. (i) Prostatic acid phosphatase (PAP) is a protein tyrosine
phosphatase, the downregulation of which is implicated in AI development (323). The
generation of RNI and ROI, which occurs during kinin signalling (Section 1.1.3.3.2.2.2.1),
results in downregulation of tyrosine phosphatases via oxidation (247). (ii) Oestrogen
signals via myc to promote MCF7 breast tumour cell survival. Phospholipase D and P13K
are upstream of myc and are necessary for this signalling pathway (301). Kinins also
activate phospholipase D and stimulate phosphoinositol hydrolysis, as does
PI3K (Section 1.1.3.3.1.3.3). It is therefore possible that kinins could promote survival in
MCF7 cells independently of oestrogen.
Also of interest, is the AI expression of PSA/hK3 in advanced prostate cancer (196). It is
possible that PSA contributes to prostate tumour progression and Al through cleavage of
IGFBP3, which results in increased availability of IGF (49).
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1.1.3.3.2.6.3 Demonstration of the KKS in prostate and breast cancer
Tissue kallikrein and B2R are both expressed in normal prostatic tissue (260, 274).
Clements and Muktahr (1997) demonstrated the expression of TK and B2R in prostate
cancer, suggesting the presence of a functional KKS in prostate cancer (274). Taub et al.
(2003) showed the expression of B 1 R in prostate cancer and its absence in normal
tissues (260). In that study, stimulation of B 1 R promoted growth, migration and invasion of
prostate tumour cells and 131R activation was shown to activate the MAPK, extracellular
signal-regulated kinase (ERK). Previously, these investigators demonstrated that kinins
transactivate EGFR in prostate cancer cells, resulting in ERK-mediated growth. One
mechanism by which B I R could promote tumour cell migration is via activation of FAK and
this activation has been demonstrated in prostate cancer cells (260). The co-presence of B I R
and B2R is necessary for proliferation of prostate cancer cells (324). The cell types used in
those studies were Al (260, 324), supporting a role for the KKS in Al prostate cancer. The
presence of TK has been demonstrated both in normal and malignant breast tissue (325) and
its involvement in the migration and invasion of OI breast cancer cells has also been
demonstrated (241). B2R is also expressed in normal and malignant breast cells and, when
stimulated by BK, promotes cell proliferation (326-328). The mitogenic effects of B2R
stimulation in normal and malignant breast cells are dependent on ERK1/2, PKC and
PLC (327).
1.1.4 Angiogenesis and the KKS in cancer therapy
1.1.4.1 Cancer therapy: anti-angiogenesis therapy
Although attention has been given to developing treatments for cancer for centuries, the
currently available therapies (surgery, radiation, chemotherapy and hormonal therapy) are
sometimes not adequate to save lives (2). According to the WHO, of the 15 million it
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predicts to be diagnosed with cancer in the year 2020, one third will die (329). The major
difficulties with available therapies are non-selectivity (resulting in toxicity) and resistance.
Anti-angiogenesis is among the new treatment approaches under development (330). These
approaches also include photodynamic therapy (331), immuno-therapy (332) and gene
therapy (333). These treatments may be used to complement conventional therapies.
Targeting of angiogenesis is attractive since most tumours are angiogenesis-dependent
(Section 1.1.2.1) and angiogenesis is largely restricted to pathological
conditions (Section 1.1.2.2). Several anti-angiogenic agents are currently being tested in
clinical trials. These include endogenous inhibitors of angiogenesis, such as angiostatin and
endostatin, synthetic inhibitors of endothelial cells, such as TNP-470 and combretastatin,
MMP inhibitors and PAls (334). Antibodies against, or synthetic inhibitors of, angiogenic
molecules, such as VEGF, VEGFR, Tie-2 and 4[4133 are also in trials (330, 334). Antibodies
against angiogenic molecules that are expressed solely by tumour vessels may be used to
deliver immuno-competent cells or toxic agents (335). A general lack of toxicity has been
observed for anti-angiogenic treatments (330, 335). There is also a lack of resistance
development for anti-angiogenic therapies that directly target the genetically stable host
endothelial cell, rather than tumour cells (330).
However, resistance may develop following treatment with indirect anti-angiogenic agents.
Indirect anti-angiogenic agents inhibit angiogenesis through either blocking the production
of pro-angiogenic agents by tumour cells or blocking the receptors for these on endothelial
cells, as opposed to direct anti-angiogenesis inhibitors (330). Resistance develops as a result
of tumour ability to change the expression of angiogenic molecules. For example, breast
tumours become less dependent on VEGF (and unresponsive to VEGF antibodies; (330))
and switch to increased FGF expression with progression (Table 1.5). Several targets for
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anti-angiogenic treatment need to be investigated in order to provide alternatives to
counteract resistance that may develop from indirect anti-angiogenic agents. Furthermore,
the molecules involved and their relative contribution to angiogenesis need to be
characterised for different tumours at different stages (330). This is because the mechanisms
of angiogenesis vary depending on the microenvironment of the different organs (318, 336).
Thus, much work remains to be done before anti-angiogenesis therapies reach the clinic.
1.1.4.2 Cancer therapy and the KKS
The KKS has recently been identified as a potential angiogenic target (Section 1.1.3.3.2.5)
that may contribute to the several candidates required for effective therapy (Section 1.1.4.1).
Angiogenesis is inhibited by BK antagonists and kallistatin (108, 293) (Section 1.1.3.3.2.5).
Considering the link between the KKS and 01/AI (Section 1.1.3.3.2.6.2), it is possible that
KKS inhibitors may be useful in treating advanced prostate and breast cancers. Evidence
suggests that this is the case for both prostate and breast cancer. BK antagonists inhibit
advanced AI prostate cancer growth in vitro (293, 337) and in vivo (in nude mice) (282,
293). and a TK inhibitor was shown to inhibit invasiveness of 01 breast cancer cells in in
vitro and ex vivo models (241).
1.2 Models investigating angiogenesis and tumour-associated angiogenesis, and
measurement of factors involved
There is a variety of in vivo and in vitro models available for investigating aspects of
angiogenesis or tumour-associated angiogenesis. The various models, and the measurement
of angiogenesis and angiogenic factors in these models, are considered below. Advantages
and disadvantages of these models for studying angiogenesis are also discussed.
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1.2.1 hi vivo models
1.2.1.1 Chick chorioallantoic membrane (cCAM) assay
The cCAM assay involves implantation of grafts onto the cCAM and monitoring of the
subsequent graft vascularisation through a glass window inserted in the shell (338). This
model may be used to study the effect of substances on angiogenesis by applying coverslips
lyophilised with the substances (including tumour-derived substances or tumour cells) to the
cCAM (339). Angiogenesis (and thereby the effect of factors on angiogenesis) was initially
quantified using an observer-dependent, subjective grading system (57, 340). However, at
present, angiogenesis may be more accurately measured by computer-assisted vessel
counting, which may be performed macroscopically or microscopically (on histological
sections of the membrane) (340).
1.2.1.2 Rabbit corneal neovascularisation model
The conical neovascularisation model is a similar concept to the cCAM assay. Insertion of
substances, tumour cells or tumour extracts into the cornea, allows their angiogenic effects to
be determined (341) through easily accessible monitoring and measurement (subjective or
computer-assisted) of corneal vascularisation using a slit-lamp stereomicroscope (340).
1.2.1.3 Pouch/chamber assays
Pouch/chamber assays involve graft implantations or implantation of exogenous materials
that are impregnated with angiogenic/test substances into the hamster cheek pouch, anterior
chamber of the eye, or subcutaneously created dorsal air sacs (57, 339). Exogenous
materials include synthetic polymers and natural substances, such as matrigel which is an
extraction from the basement membrane matrix of Englebreth-Holm-Swarm tumours (from
lathyritic mice) that contains ECM components and growth factors (340, 342). Models using
transparent chambers allow for subjective/computer-assisted measurement of angiogenesis
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over time using transillumination technology, whereas models using exogenous implants
allow measurement at one time-point only. Following 1-2 weeks, exogenous implants may
be examined for an angiogenic response by measurement of haemoglobin content or by
immuno-histochemical analysis using endothelial markers (340).
1.2.1.4 Advantages and disadvantages of in vivo models
A common disadvantage of in vivo models is that tissue injury and subsequent inflammation
that occurs in the process of graft/polymer/matrigel implantation may itself induce
angiogenesis, interfering with interpretation of results (340, 343). The presence of naturally
occurring blood vessels in in vivo models also obscures results. The corneal model is an
exception since the cornea is normally avascular (338). In vivo models are also generally
complicated, expensive and may require specific surgical skills (340). Due to the many cell
types and factors present, in vivo models cannot answer certain questions (344). For
example, the effect of tumour cell metabolites on endothelial cell activities cannot be
determined in an in vivo model as metabolites of various cells are present.
1.2.2 In vitro models
In vitro models have an advantage over in vivo models in that they are generally less
expensive, simple, variables are more easily controlled than in in vivo models, and they are
comparatively easy and quick to execute (340). Some in vitro models have an added
advantage of allowing various aspects of angiogenesis, namely proliferation, migration,
invasion, and differentiation, to be studied separately (Sections 1.2.2.1 and 1.2.2.2). In vitro
models also allow analysis of the effect of a single factor on angiogenic events. In the
future, identification of the precise contribution of a specific gene to an angiogenic event
will be possible with genetically modified endothelial cells (345). However, data derived
from in vitro models is not as conclusive as that arising from in vivo models (340).
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Therefore, in vivo models are required to confirm or test implications of results obtained
with in vitro models. Specific interactions between particular cell types or factors that
cannot be answered by in vivo models may be analysed by in vitro models that arc limited to
I or 2 cell types. In vitro models are either 2D or 3D and involve either the culture of 1 cell
type or 2 cell types together (co-culture) or a tissue explant.
1.2.2.1 2D models: endothelial proliferation, migration and differentiation
Cells may be cultured onto a plate and fed with a medium containing nutrients until they
form a confluent 2D monolayer. Conditioned medium (i.e. medium that contains cell
metabolites derived from a growing mass of cells) may be included in the mixture fed to
cells to improve their growth at low cell densities (346). A similar concept is the
"challenging" of endothelial cells with conditioned medium from a tumour cell culture in
order to study the effects of tumour cell metabolites on angiogenesis (71, 296).
Proliferation and migration aspects of angiogenesis may be considered separately using 2D
models. Various proliferation assays, for example tetrazolium salt assays and assays
involving incorporation of thymidine or 5-bromodeoxyuridine into DNA, are available and
may be performed on endothelial cells in 2D culture (340, 347). Migration may be
investigated in isolation with a 2D "wound healing" migration assay (260). This involves
disruption of a 2D monolayer and counting of cells that subsequently migrated into the
"wounded area" after a set period of time. The Boyden chamber assay may also be used to
measure endothelial motility and the effect of specific factors on this aspect of
angiogenesis. Endothelial cells are plated in upper chambers, which are separated from
lower chambers by a filter. The lower chambers contain a test substance and the cells that
have migrated through the filter in response to the test substance may be stained and
counted (338, 340).
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When maintained for long periods, 2D cultures of endothelial cells differentiate to form
capillary-like networks (or cord-like structures) representing, and allowing study of, the
latter stages of angiogenesis (71). This stage of angiogenesis may be analysed by measuring
the number and length of tubes, the area covered by the capillary network or the number of
branches in the cord-like structures (340). The differentiation of endothelial cells into cord-
like structures is mostly studied using 3D matrix models (Section 1.2.2.2), which incorporate
all aspects of angiogenesis - endothelial proliferation, migration and differentiation, as well
as invasion.
1.2.2.2 3D models: endothelial proliferation, migration, invasion and differentiation
Culturing of endothelial cells on collagen, fibronectin or fibrin gels or matrigel results in a
3D angiogenic model as endothelial cells invade the matrix and form networks within these
gels (296, 348, 349). Collagen gels are useful for identifying factors that induce invasion or
cord-like structure formation (345). Matrigel represents in vivo angiogenesis conditions (in
the later stages) more accurately than other 3D gel models and is the most commonly used to
investigate endothelial differentiation into cord-like structures (338, 345). Matrigel may also
be incorporated into the Boyden chamber assay in order to test the effect of factors on
migration and invasion aspects of angiogenesis simultaneously (340, 350). In addition to
staining and counting cells that have migrated and invaded through the gel-coated filter, the
option of radiolabelling endothelial cells, followed by scintillation counting, is available to
measure migration and invasion (350).
A 2D cell culture system has an advantage over a 3D model in that it is much simpler to
analyse and visually interpret with microscopy-based methods (272), which include
immuno-chemistry and polymerase chain reaction (PCR). Immuno-labelling and PCR
methods allow detection/quantification of the presence and expression of specific factors in
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the angiogenic models, respectively. If thick gels with embedded cells are used in 3D
models, they must be fixed, embedded in supporting medium and sectioned prior to
immuno-labelling (351). Unsectioned, thin gels with cells plated on top do not require this
preparation; however, a proportion of cells (that penetrate the gel deeply) are not accessible
for labelling or analysis. Another disadvantage of 3D models is that, although they may be
analysed by solution PCR or reverse transcriptase (RT-) PCR (3 5 2), they are not suitable for
in situ PCR analysis. However, since cellular shape and environment influence gene
expression and biological behaviour of cells (3 4 5) (Section 1.1.2.5), the complexity of 3D
models (although disadvantageous in some respects) has the advantage of more closely
representing in vivo conditions than 2D models (344).
1.2.2.3 Co -culture models
Angiogenesis is influenced by many cell types present in the environment of endothelial
cells (Section 1.1.2.4). Thus, more accurate representations of in vivo conditions are co-
culture models and the aortic ring model (3 4 9). Co-culture models may be used to study the
influence of one cell type on another, such as the influence of smooth muscle cells on
endothelial cell angiogenic activity (3 4 9) and the influence of tumour cells on endothelial
cells and vice versa with respect to expression of KKS components (2 7 2). The aortic ring
model involves culturing of rat or mouse aorta in biological matrices, which results in out-
branching of microvessels (353). These microvessels may be quantified subjectively or
using computer-assisted image analysis. Mural cells and fibroblasts are also present in this
model. Thus, the aortic ring model has aspects of both in vivo and in vitro models and it is
also sensitive, reproducible and quantitative. However, large blood vessels used in this type
of study are a disadvantage of the aortic ring model as, in vivo, new vessels formed by
angiogenesis are generated from microvessels (3 4 0). Additionally, it is not easy to identify
the exact role of each cell type in the events leading to capillary tube formation (3 4 5).
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1.2.3 Choice of models for the present study
In the present study, in vitro models were chosen in preference to in vivo models due to the
complicated nature and cost of in vivo models, as well as the surgical skill often required in
their implementation (Section 1.2.1.4). Further, in vivo models are not conducive to the
study of specific cell interactions, whereas in vitro models are suitable for this purpose.
A 2D "challenge" model (Section 1.2.2.1), involving the challenging of endothelial cells in
culture with tumour-conditioned medium and vice versa, was chosen to investigate the effect
of tumour cell metabolites on endothelial cell expression and secretion of the KKS proteins,
as well as their effect on endothelial cell proliferation and vice versa. Endothelial and
tumour cells were also co-cultured on a 2D surface in order to investigate the role of the
KKS in direct endothelial-tumour cell interactions.
1.3 The present study: rationale, aims and hypothesis
Due to the potential tumourigenic and angiogenic role of the KKS (Section 1.1.3.3), and the
potential therapeutic benefits of targeting the KKS involvement in tumourigenesis/tumour-
associated angiogenesis (Section 1.1.4), the present study aims to further investigate the role
of the KKS in tumour angiogenesis. It extends the work of Naidoo (354), which focused on
neuroblastomas and cervical carcinoma, by using cells of two different tumour types, namely
prostate (DU145) and breast (MCF7) cancer. Prostate and breast tumours were chosen as
they develop in men and women, respectively, more frequently than any other cancer type,
and understanding of their pathogenesis is incomplete (355). There is also evidence for the
contribution of the KKS to tumour progression and hormone independence in both prostate
and breast cancer (Section 1.1.3.3.2.6). Further, the KKS may be a therapeutic target for
these cancers, particularly for the Al/OI forms, for which therapy is currently inadequate
(Section 1.1.3.3.2.6.1). The present study also extends the work of Naidoo, in which
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macrovascular endothelial cells were used. by using microvascular endothelial
cells (MVECs). Angiogenesis in vivo occurs with microvessels rather than
macrovessels (347) and therefore the culture of MVECs more closely represents
angiogenesis in vivo.
Since the activities of the KKS have been linked to the promotion of tumourigenesis and
tumour angiogenesis, and since there is some evidence for a tumourigenic role for the KKS
in prostate and breast cancer, it is expected that the KKS would promote tumour
angiogenesis and therefore tumourigenesis in prostate and breast cancer. To test this
hypothesis, the present study aimed to investigate the role of the KKS in tumour
angiogenesis, specifically in prostate and breast cancer by:
• determining the effect of tumour cell metabolites on KKS regulation (expression and
secretion) in endothelial cells and vice versa
• determining the effect of tumour cell metabolites on endothelial cell proliferation and
vice versa, and relating this to the effect of these metabolites on KKS regulation
• investigating the role of the KKS in direct endothelial cell-tumour cell interactions
To do this, the following objectives were fulfilled:
• optimisation of in vitro challenge and co-culture endothelial-tumour cell models in
order to investigate MVEC-breast/prostate tumour cell interactions
• investigating the KKS within these models using immuno-cytochemistry
• investigating the KKS within the challenge model using enzyme-linked
immunoassay (ELISA)
• measurement of endothelial and tumour cell proliferation within the challenge model






CHAPTER 2 - MATERIALS AND METHODS
2.1 Ethics
Ethical approval was obtained from the Biomedical Ethics Committee of the Nelson R
Mandela School of Medicine, University of KwaZulu-Natal. Human cell lines were
commercially obtained and human salivary gland, kidney and spinal cord control tissues
were previously collected from the KwaZulu-Natal Department of Health State Mortuary
with the assistance and permission of a forensic pathologist.  TK, B I R and B2R
antibodies (354), used for immuno-chemistry and ELISA, had been previously raised in and
collected from animals [by the research unit in the Department of Clinical and Experimental
Pharmacology, Faculty of Medicine, former University of Natal, in conjunction with the
Biomedical Resource Centre (BRC), former University of Durban-Westville] with the
ethical permission of the former University of Durban-Westville Ethics Committee.
2.2 Cell culture
2.2.1 Source of cell lines and constituents of cell culture media
A dermal microvascular endothelial cell (dMVEC) cell line (passage 3) was purchased from
Clonetics, BioWhittaker (Walkersville, USA). The frozen 1 ml aliquot was stored in a
—85°C ultrafreezer (NuAire, USA) until use. The medium (BioWhittaker) used to culture
dMVECs consisted of endothelial basal medium (EBM-2, 500 ml) pre-supplemented with
foetal bovine serum (FBS, 25 ml), recombinant human fibroblast growth factor-beta (rhFGF-
(3, 2 ml), vascular endothelial growth factor (VEGF, 0.5 ml), hydrocortisone (0.2 ml), R 3
-insulin-like growth factor (R3 -IGF-1, 0.5 ml), ascorbic acid (0.5 ml), human endothelial
growth factor (hEGF, 0.5 ml) and antibacterial agent (GA-1000, 0.5 ml). Medium was re-
constituted in a sterile field: a class II microbiological cabinet with vertical laminar airflow
and curtain. Once re-constituted, medium was stored at 4°C for not more than 3 months.
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Frozen 2 ml aliquots of DU145 prostate tumour and MCF7 breast tumour cell lines were
commercially obtained from Highveld Biological, National Repository for Biological
Material of the Cancer Association of South Africa (Sandringham, SA). On arrival, they
were immediately stored at —85°C. DU145 medium consisted of Dulbecco's modification of
Eagle's minimum essential medium (DMEM) supplemented with 10% FBS, penicillin-
streptomycin-fungizone (PSF; 200 pg/ml) and L-glutamine (2 mM). Similarly, Eagle's
minimum essential medium (EMEM) supplemented with 10% FBS, PSF (100 µg/m1),
L-glutamine (4 mM) and sodium pyruvate (1 mM) constituted medium used to culture
MCF7 cells. All tumour media constituents were purchased from BioWhittaker. Media
were re-constituted in a sterile field, and thereafter stored at 4°C for not more than 2-3
weeks.
2.2.2 Preparation of work area and equipment
Culturing of cells and preparation of media were performed in a sterile biological
cabinet. The biological cabinet and all cell culture equipment stored therein (pipettes,
pipette tips and culture dishes) were subjected to UV light (100-400 nm) for an hour prior to
use. Glass pipette tips (LASEC, SA) and plastic pipette tips (Greiner, Germany) were
autoclaved at 121°C for 20 minutes. [The glass pipette tips were used in conjunction with a
hand-held electronic pipette (Powerpette Plus, Jencons, USA), whilst plastic pipette tips
were used in conjunction with a mechanical pipette (Gilson, France)]. All work surfaces and
cell culture equipment were swabbed with 70% ethanol (Merck, SA) and/or antibacterial
solution [Virkon (Antec, SA), 0.02 g Virkon in 1m1 distilled, deionised water (ddH 20)] and
left to settle for 10 minutes before working. [Water was distilled and deionised by a Milli-
U6 water purification system (Millipore, SA).] Items such as media bottles and centrifuge
tubes (Greiner) were swabbed before they were introduced into the biological cabinet.
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Gloves were sprayed with 70% ethanol immediately prior to opening the incubator, handling
the cultures and working in the biological cabinet.
2.2.3 Thawing of cryo -stored cell cultures, plating and maintenance in culture
Cryo-vials (Corning-Costar, USA) were immediately transferred from the —85°C ultrafreezer
to a 37°C vs. aterbath and allowed to thaw, with frequent agitation, for 3 minutes (354, 356) .
The contents of the vials were pipetted into either p60 (21 cm 2) or p100 (55 cm2) culture
dishes (Corning-Costar) containing fresh, pre-warmed cell-specific media [warmed for 10-15
minutes in a humidified incubator (Function Line, Heraeus, Germany), at 37°C/5% CO,].
The final volumes of medium used for a p60 and p100 were 4 ml and 8 ml, respectively.
The surface area for plating was determined by the following formula:
Surface area (cm 2 ) = number of cells per vial / plating density (cells/cm 2 )
The plating density of the primary dMVEC cell line and tumour cell cultures was
recommended by the respective suppliers. Thereafter, plating densities that yielded
approximately 60% confluency after 2 days in culture were used as this was required for
challenge experiments (Section 2.2.6.1). These plating densities were 2000 cells/cm 2 , 3500
cells/cm2 and 1500 cells/cm 2 for dMVECs, DU 145 cells and MCF7 cells, respectively.
After plating, cells were incubated in the humidified incubator for 24 hours, at which point
most cells had attached to the bottom of the culture dish. Following this, the medium from
the culture dish was aspirated and cells were supplied with fresh pre-warmed medium. Only
one cell line was fed at a time, with a half-an-hour interval in between feeding different cell
lines in order to minimise cross-contamination. Subsequently, the medium was changed
every 48 hours or when the phenol red in the basal medium turned yellow, indicating a need
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to feed the cells fresh medium. The growth of cultures was monitored using a phase
contrast, bright field inverted microscope (DMIL, Leica, Germany) that was swabbed with
70% ethanol prior to use.
2.2.4 Passaging
Cells were passaged upon reaching 80-90% cell confluency (354, 356). Try psin-versene
(BioWhittaker) was used to enzymatically detach cells from the surface of the culture dish.
First, medium was removed from the culture dish and replaced with pre-warmed phosphate
buffered saline (PBS, BioWhittaker), swirled gently for 30 seconds and then aspirated and
discarded in order to remove serum proteins and debris. The cells were then incubated at
37°C with pre-warmed trypsin. The volume of trypsin used was 2 ml for a p60 and 4 ml for
a p100. Upon rounding (i.e. retraction of membrane extensions) of at least 90% of the cells,
trypsin was immediately inactivated by adding medium at twice the volume of trypsin used.
Cells were not incubated with trypsin for more than 3 minutes (in order to minimise
irreversible trypsin-induced cell damage) and were frequently viewed with the inverted
microscope during this period in order to determine when to stop the trypsin activity. The
trypsinised cells were then centrifuged at 1000 rpm/180 x g for 5 minutes (Megafuge 1.0R,
Heraeus, Germany) and resuspended in fresh growth medium. The volume of cell
suspension required to plate cells at the density desired (optimised to result in 60%
confluency 2 days after plating, Section 2.2.3) was calculated using the following formulas:
number of cells required = plating density (cells/cm 2) x surface area (cm2 )
volume of cell suspension (ml) = number of cells required/cell concentration (cells/ml)
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The concentration of cells in the cell suspension was determined using a
haemocytometer (Neubauer, Assistant, Germany). A haemocytometer is a slide that draws
fluid by capillary action over its coverslipped grid when fluid is pipetted into a groove on
either side of the grid (Figure 2.1). The grid forms 8 large squares (4 large squares on either
side of the slide) each of volume 0.1 mm 3 . These are each subdivided into 16 smaller
squares. Cells were counted with a phase contrast, bright field microscope (DMLB, Leica,
Germany). Cells on the top and left lines of the smaller squares (if lines were adjacent to
those of other small squares) were excluded from the count to avoid counting the same cell
twice (356). If the combined cell number of 4 large squares was less than 100, the 4 squares
on the other side of the slide were also counted and an average taken. Since 0.1 mm 3 is
equivalent to le ml, the average cell number for the large squares was multiplied by 10 4 to
determine the cell concentration of the cell suspension (cells/rill). In order to avoid including
non-viable cells in the calculation of cell concentration, a trypan blue viability assay was
performed in conjunction with cell counts. This is a rapid, well-established method to test
viability, in which trypan blue may be substituted for other dyes (erythrosine and
naphthalene black) to which intact cell membranes are also impermeable (356). Trypan
blue (0.4%, Sigma, St. Louis, USA) was added to cell suspension in an eppendorf
tube (Eppendorf, UK) in a 1:1 ratio prior to pipetting 25 1..11 of the mixture into the groove on
either side of the haemocytometer. Cells that had taken up the blue dye (cells with
irreversibly compromised membrane integrity i.e. non-viable cells) were excluded from the
cell count. Thus, only viable cells that had excluded the dye were counted. Cell counts were
performed within 5 minutes since trypan blue is toxic to cells and this results in
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2.2.5 Cryo-preservation
A cell bank was built up simultaneously with the passaging of cells to ensure sufficient
stocks for performing challenge and co-culture experiments. The proportion of cells stored
and the proportion plated depended on the cell yield and the most favourable balance
between the quantities of cells required in culture and the level of stock. (A cell log was
kept in order to keep track of the amount of stock from each passage.) After performing cell
counts and plating, dimethylsulfoxide (DMSO, Sigma) was added to the remainder of the
cell suspension such that the final volume comprised 10% DMSO (356). The cell count was
then repeated for the purpose of recording the cell number per cryo-vial stored. The cryo-
vials containing the 10% DMSO-cell suspension mixture were transferred to a polystyrene
container in a —85°C ultrafreezer within 20 minutes of adding the DMSO but not before
10 minutes of exposure to DMSO (354). This was to ensure enough time for DMSO to
penetrate the cells while minimising the toxicity of over-exposure to DMSO. DMSO is a
cryo-protectant that penetrates cells and increases the intracellular solute concentration
thereby minimising damaging "solution effects" on cooling (357). It also either decreases
the amount of intracellular ice formed (357) or promotes intracellular vitrification (formation
of an amorphous protein-sugar-water glass matrix) instead of lethal intracellular ice crystal
formation upon cooling (358). The cooling rate achieved by insulating cells in a polystyrene
container in a —85°C ultrafreezer is approximately 1°C per minute (356), a cooling rate
found to yield sufficient cell survival for most animal cells (356, 359). The day after storing
the cells, they were transferred to a cryo-vial freezer box in the —85°C ultrafreezer. When
the use of cells in stock was required to perform experiments, thawing of cryo-preserved
cells was performed fairly rapidly [in order to minimise damage on thawing, which could
result in formation of large lethal intracellular ice crystals if warming is too slow (358)] by
transferring them to a 37°C waterbath with frequent agitation for no longer than 3
minutes (356) (Section 2.2.3). The contents of cryo-vials were pipetted onto a plate of pre-
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warmed medium immediately after thawing and medium was changed 24 hours later,
thereby minimising cell damage due to DMSO exposure.
2.2.6 Endothelial -tumour models
The endothelial-tumour challenge and co-culture models of Naidoo (2005) were now
optimised for dMVECs, DU145 cells and MCF7 cells (354). Cells growing in culture were
trypsinised and used for challenge/co-culture experiments or cryo-preserved cells were
thawed, first plated onto a p60 or p100, grown to confluency, trypsinised and then used for
experiments. Only dMVECs of between passages 4 and 12 were used in order to ensure that
they retained their characteristics. Since tumour cells are immortal, tumour cells of any
passage number were used in experiments.
2.2.6.1 2D Challenge model
The dMVECs, DU145 cells and MCF7 cells were seeded onto 8-well glass chamber slides
(Iwaki, Japan) at 2000 cells/cm 2, 3500 cells/cm`' and 1500 cells/cm 2 , respectively. These
optimal densities resulted in cells reaching approximately 60% confluency after 2 days.
Cells were simultaneously plated onto a p60 dish for each cell line. Plating and maintenance
of cultures is described in Section 2.2.3. After 2 days in culture (at a confluency of
approximately 60%), used (conditioned) media were collected from the p60 dishes with
dMVEC, MCF7 and DU145 cell lines, respectively. Used media were then filtered through
0.45-rim filter-syringes into 15 ml tubes. Used medium from the dMVEC line was mixed
with both fresh DU145 medium and fresh MCF7 medium in ratios of 0%, 10%, 25% and
50% (challenge media). Similarly, used media from the DU145 and MCF7 tumour cell lines
were each mixed with fresh dMVEC medium in ratios of 0%, 10%, 25% and 50%. The
various challenge media were then warmed in a waterbath at 37°C. Thereafter, the tumour
cells and endothelial cells in the chamber slides were challenged with the different ratios of
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used/conditioned media (containing metabolites) from endothelial cells and tumour cells,
respectively, in duplicate, as depicted in Figure 2.2. After 24 hours, challenge media were
aspirated from the chamber slides and saved for the TK ELISA (Section 2.3.3). For each
cell line, challenge medium was replaced by serum-free cell-specific medium and cell lines
were incubated for a further 24 hours. Thereafter, cells were rinsed in PBS and fixed in
acetone (Merck, SA)/methanol (Merck) in a ratio of 1:9 (v/v) for 20 minutes at — 20°C.
Thereafter, immuno-cytochemistry was performed on the cells.
2.2.6.2 2D Co-culture model
Tumour cells were plated onto p60 culture dishes and weaned onto dMVEC medium in order
to prepare for co-culture of tumour cells with dMVECs. The dMVECs were seeded onto
glass chamber slides at an optimal density of 2000 cells/cm 2 that resulted in their adherence
and establishment 24 hours after plating, at which point the tumour cells on the p60 dishes
were 80-90% confluent. The tumour cells were then trypsinised (Section 2.2.4) and the
DU145 and MCF7 cells added at 2500 cells/cm 2 and 2000 cells/cm`, respectively, to the
glass chamber slides with the dMVECs. Maintenance of these co-cultures is described in
Section 2.2.3. Once the tumour cells had begun to proliferate in the co-cultures and
heterogeneous cell contact was observed with an inverted microscope (typically within 24
hours), the co-cultures were serum-cleared. After a further 24-hour-incubation, cells were
rinsed and fixed as for the challenge model (Section 2.2.6.1), followed by immuno-
cytochemistry. Figure 2.3 is a diagrammatic representation of the co-culture model.
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1. Plating and maintenance in culture
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2.3 Analysis of challenged cells and co-cultured cells
2.3.1 Overview
Fixed challenged and co-cultured cells were analysed by immuno-cytochemistry (Section
2.3.2.3 and 2.3.2.4) followed by quantification of labelled proteins in challenged
cells (Section 2.4). This allowed for both intracellular localisation of TK, B1R and B2R
with subsequent relation to their functions, and determination of how the challenge
metabolites affected the intracellular levels of these proteins. Additionally, media were
collected from slides of the 2D challenge model after challenging and analysed by ELISA
for TK protein concentration (Section 2.3.3) in order to relate secretion of TK to intracellular
protein levels (measured by immuno-cytochemistry) and the concentration of
tumour/endothelial challenge metabolites. The challenge model was also performed in a 96-
well plate and these cells were analysed by the 3-(4,5-dimethylthiazol-2-y1)-2,5-diphenyl
tetrazolium bromide (MTT) assay for cell proliferation (Section 2.3.4) in order to ascertain
the effect of challenge metabolites on their proliferation.
A set of 4 slides (including slides labelled for TK, B I R and B2R and a negative control
slide) was required for immuno-cytochemistry analysis for each challenge combination. The
4 challenge combinations are depicted in Figure 2.2. For the MTT assay analysis, a 96 -well
plate for each challenge combination with a respective control (Section 2.3.4.2), performed
with 5 replicates for each challenge condition and control, was required. A slide (including
duplicate wells for TK, B1R, B2R and a negative) for each co-culture combination
(dMVEC-DU145 and dMVEC-MCF7) was required for analysis by immuno-cytochemistry.
The overall study design described above is depicted in Figure 2.4. A brief background and
detailed description of the methods of analysis used in this project follows.
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I mmuno-chemistry allows visualisation of specific cell proteins through the binding of
detectable primary antibodies that are specific for these proteins (360, 361). These primary
antibodies can be detected by the binding of a secondary antibody that is conjugated to a
marker. Binding of a secondary antibody to a primary antibody is achieved by the selection
of a secondary antibody that will react with antibodies from the host of the primary antibody.
For example, if the primary antibody used is rabbit anti-human TK antibody then the
secondary antibody used would be an anti-rabbit antibody conjugated to a marker. Markers
may be fluorescent dyes (detected by a fluorescent microscope), gold/silver (detected by a
light microscope) or enzymes that convert substrate to a coloured product (detected by a
light microscope) (109, 360, 361). The most common enzyme marker is horseradish
peroxidase and the most useful and widely used substrate for peroxidase is diaminobenzidinc
(DAB) (361). This enzymatic reaction is most often employed in the avidin-biotin complex
(ABC) method of immuno -chemistry (360, 361), as used in the present project [Section
2.3.2.2.4, Figure 2.5(i)]. In this method, secondary antibody is biotinylated and horseradish
peroxidase is conjugated to streptavidin, which has 4 binding sites for biotin. Thus,
peroxidase becomes localised to the site of the target antigen. Peroxidase then converts
DAB to a brown-coloured product. In order to increase the signal, streptavidin molecules
are complexed to biotinylated peroxidase, such that there are only biotin-binding sites
available on the complex, which bind to the biotinylated secondary antibody, thereby
increasing peroxidase number per antigen locus. Another common enzyme marker, which
was used in this project, is alkaline phosphatase (361). Alkaline phosphatase converts fast



















(ii) Alkaline phosphatase-fast red method
target protein
//     
coloured
substrate    






phosphatase           
enzymatic
reaction                
fast red             
75
2.3.2.2 Immuno-chemistry on tissue controls
Normal human submandibular gland, spinal cord and kidney were used as positive controls
for TK, B1R and B2R, respectively. TK is abundant in the submandibular and parotid
salivary gland striated and interlobular ducts and is absent in the acini and intercalated ducts
of these glands (362). B I R has been localised in neurons of the dorsal horn of the spinal
cord and was therefore chosen as the control tissue for B 1 R (354). B2R is present in a wide
range of tissues; however, kidney was chosen as the control tissue as it is an abundant source
of B2R (363). In particular, B2R is found in the mesangium of the glomeruli, proximal and
distal tubules, loop of Henle, collecting ducts and endothelial cells of blood vessels of the
human kidney (266). These control tissues were previously collected from the KwaZulu-
Natal Department of Health State Mortuary with the assistance and permission of a forensic
pathologist (Section 2.1).
2.3.2.2.1 Silanation of slides for immuno-chemistry and haematoxylin and eosin
(H&E) staining
Glass slides were silanated in order to enhance the adherence of tissues (364). Slides were
immersed in a 2% 3-aminopropyltriethoxysilane (Sigma) solution with acetone as the
solvent, for 10 minutes. The silane solution was made up fresh and used immediately.
Excess silane was washed off in acetone for approximately 30 seconds. Slides were then
immersed in dd1-120 for 30 seconds in order to wash off excess acetone. All the above steps
were carried out at room temperature. Slides were dried overnight in the oven at 50°C.
2.3.2.2.2 Sectioning of control tissues for immuno -chemistry and H&E staining
Control tissues embedded in wax blocks were cut into sections of 4-5 ..an thickness using a
rotary microtome (Leica). Sections were then floated in a waterbath at 60°C in order to
flatten out creases and were subsequently picked up onto silanated slides (Section 2.3.2.2.1).
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Slides were then dried overnight in the oven at 50°C, ensuring proper adherence of sections
to slides.
2.3.2.2.3 Selection of non-diseased control tissues — H&E staining
Different salivary gland, spinal cord and kidney blocks were sectioned and picked up onto
slides that were previously silanated as described in Sections 2.3.2.2.1 and 2.3.2.2.2. These
sections were stained with haematoxylin and eosin using routine methodology (361) and
viewed with a bright field light microscope in order to ensure the use of normal tissue as
controls. Tissues were dewaxed by immersion in 2 changes of xylene (Merck), each for 10
minutes. This was followed by rehydration in a series of increasingly dilute ethanol
solutions (100%, 90%, 70% and 50%) for 5 minutes each, followed by 5 minutes in ddH 2O.
Tissues were then stained with Mayer's haematoxylin (Sigma) for 5 minutes at room
temperature in order to stain nuclei blue. Haematoxy lin was washed off in running tap water
for 5 minutes. Tissues were then counterstained with eosin (Sigma), which had been diluted
to 0.5% with glacial acetic acid (Merck), for 5 minutes at room temperature in order to stain
cell membranes and cytoplasmic structures pink. Eosin stain was washed off in running tap
water for 5 minutes. Tissues were then dehydrated in a series of increasingly concentrated
ethanol solutions (50%, 70%, 90% and 100% ethanol) for 5 minutes each. They were then
immersed in xylene for 5 minutes before mounting with glass coverslips (Bectin Dickinson
Biosciences) and permanent mountant, DPX (Merck). Only the tissue blocks that were
confirmed as normal after analysis of H&E stained sections were sectioned for use as
immuno-cytochemistry controls (as described in Section 2.3.2.2.2). The kidney blocks used
in the present project were also examined and declared histologically normal by
histopathologist Dr. Ashwin Bremdev, Lancet Laboratories. Durban.
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2.3.2.2.4 Immuno-chemistry protocol for control tissues
The immuno-chemistry protocol of Naidoo (2005) was followed and is described
below (354). This protocol was a modification of previous immuno-chemistry
protocols (187, 365, 366).
Dewaxing and rehydration of tissues- Tissues were dewaxed by immersion in 2 changes of
xylene, each for 10 minutes. This was followed by immersion in 100% ethanol twice, each
for 5 minutes, in order to clear xylene from the sections. Endogenous peroxidase activity
was partially inhibited by immersing tissues in 100% methanol (Merck) (361, 367) for 20
minutes. This was done in order to avoid non-specific binding of peroxidase to the
streptavidin of horseradish peroxidase-streptavidin conjugate, which would result in non-
specific labelling of peroxidase-containing structures such as red blood cells. Tissues were
then rehydrated in a series of increasingly dilute ethanol solutions (90%, 70% and 50%) for 4
minutes each, followed by immersion in 100% ddH 2O for 5 minutes. All above steps were
carried out at room temperature.
Antigen retrieval- Antigen retrieval refers to the unmasking of antigens that were modified
by formalin fixation, in order to improve antigenicity (368). This is an important step for
satisfactory immuno-staining. Antigen retrieval was performed by heating tissues to
approximately 80°C for about 7 minutes in 0.1 M tri-sodium citrate dihydrate (Merck)
solution, pH 6. This was achieved by heating a container of the sodium citrate solution with
immersed slides on high temperature in a microwave oven (R-4A52; Sharp Corp., Japan)
until the solution began to bubble (after approximately 2 minutes). The settings were then
immediately switched to low temperature for 5 minutes. The tissues in the boiling sodium
citrate solution were allowed to cool to room temperature (for approximately 20 minutes)
and were then equilibrated in ddH2O for 5 minutes.
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Quenching of endogenous peroxidase activity and blocking of non -specific sites- Further
quenching of endogenous peroxidase activity was carried out in 4 changes of hydrogen
peroxide (Merck)-methanol (4 parts 30% H202 [i.e. 12% H202] and 6 parts absolute
methanol), for 15 minutes each at room temperature. H202 acts as a substrate for peroxidase
and irreversibly inhibits the activity of the enzyme presumably due to structural damage or
as a result of the high substrate concentration or accumulation of a toxic product (360).
Although H202-methanol inhibits endogenous peroxidase activity, it allows for the activity
of the horseradish peroxidase (369). The tissues were then washed twice in Tris-buffered
saline ( IBS)/3% bovine serum albumin (BSA; Boehringer Mannheim, Germany) for 5
minutes each time at room temperature. TBS was prepared as 5% Tris-hydrochloric
acid (Tris-HC1; 1 M Trizma Base (Sigma), adjusted to pH 7.5 with 30% HCI [Merck]) and
3% sodium chloride (5M NaCI; Merck). A 3% solution of BSA was then made up using
TBS. The function of BSA was to block non-specific antibody/reagent-binding sites.
Following the TBS/3%BSA washes, non-specific antibody-binding sites were further
blocked for 1 hour at room temperature in 10X concentrated milk blocker (DIG Wash and
Block Buffer Set from Roche, Mannheim, Germany) that was diluted to 1 X in TBS/3%BSA.
Source of primary antibodies, optimal antibody dilutions and incubation with primary
antibodies- Whilst the tissues were incubating with the blocking solution, the primary
antibodies were thawed on ice (antibodies were stored frozen at —20°C) and dilutions of
these (refer to Detection of bound primary antibody), using the 1 X milk blocker solution,
were made up on ice. Polyclonal anti-human goat TK antibody and polyclonal rabbit B1R
and B2R antibodies (refer to Section 2.1) (272) were used to label TK, BIR and B2R,
respectively. After the tissues had been blocked for 1 hour in milk blocker, they were
incubated with the diluted primary antibodies in a humified chamber at 4°C for 18 hours.
Negative tissue controls were incubated with 1X milk blocker solution instead of antibody.
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Detection of bound primary antibody- Following the 18-hour incubation with antibodies,
unbound antibody was washed off in 2 TBS/3%BSA washes, for 2 minutes each. Tissues
were then blocked in I X milk blocker solution twice, each time for 30 minutes at room
temperature, in order to block non-specific binding sites for the secondary antibody.
Thereafter, kidney tissues were additionally blocked for biotin via the avidin-biotin 'flush'
method (360, 361) using a biotin blocking kit (Dako, UK) with an avidin solution (incubated
for 15 minutes) and biotin solution (incubated for 15 minutes). Biotin blocking was
necessary to prevent non-specific binding of streptavidin (horseradish peroxidase-
streptavidin conjugate) to biotin, which would result in non-specific labelling of biotin-
producing cells of the kidney. Following biotin blocking, all tissues were washed twice for 2
minutes each with TBS/3%BSA. The ABC conjugating kit (LSAB Plus, Dako) was then
used on the tissues. This involved incubating the tissues for 20 minutes with a secondary
lgG-type multi-species antibody linked to biotin, followed by a 20-minute incubation with
streptavidin-peroxidase solution with TBS/3%BSA washes before and after. Tissues were
then incubated with DAB in the dark for approximately 5-7 minutes. The tissues were
monitored with a bright field light microscope (Leica) and DAB was inactivated by
immersing tissues in TBS/3%BSA once adequate specific brown staining of structures was
observed. All kits described above were used at room temperature and incubations were in a
humidified chamber. Following the incubation with DAB, slides were counterstained with
May er's haematoxylin for 3-5 min at room temperature to produce a colour contrast between
the brown DAB-labelled cellular structures and blue haematoxylin-stained nuclei. The
excess hacmatoxylin was subsequently washed off in running tap water for 5 minutes.
Tissues were then dehydrated and mounted as for H&E stained sections as described in
Section 2.3.2.2.3. Results were viewed with a bright field light microscope. The optimal
dilutions of the TK, B 1 R and B2R primary antibodies for salivary gland, spinal cord and
kidney tissues were determined to be 1:5000, 1:150 and 1:150, respectively.
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2.3.2.3 lmmuno-cytochemistry on challenged cells and cell culture controls
Firstly, cells were partially permeabilised (in order to allow accessibility of reagents) by
treatment with 1% Triton X100 (Merck) for 20 minutes at room temperature. A 2-minute
TBS/3%BSA wash was then performed to stop the reaction. Cells were then incubated with
I X milk blocker for I hour at room temperature. This was followed by an 18-hour
incubation with diluted antibody at 4°C in a humified chamber. The remainder of the
immuno-chemistry protocol for cells was the same as that used for tissues following the
primary antibody incubation onwards (Section 2.3.2.2.4). Optimal antibody dilutions for
cultured cells for TK, B 1 R and B2R, respectively, were determined to be: (i) 1:50, 1: 100
and 1: 50 for dMVECs, (ii) 1:150, 1:400 and 1:75 for DU145 cells, and (iii) 1:650, 1:750 and
1:200 for MCF7 cells. Negative cell culture controls were incubated with 1X milk blocker
solution instead of antibody.
As positive cell culture controls, endothelial cells were labelled for von Willebrand's factor
(vWF), a specific marker of endothelial cells (370, 371), and DU145 cells and MCF7 cells
were labelled for cytokeratin-19 (CK-19), a marker for breast and prostate tumour
cells (372). The vWF was labelled with rabbit anti-human vWF IgG (Dako) that was raised
against vWF isolated from human plasma. CK-19 was labelled with murine anti-human CK-
19 IgG (Dako). This antibody was raised against T24 human bladder cancer extract. The
antibody dilution used for both vWF and CK-19 was 1:200.
2.3.2.4 Immuno -cytochemistry on co -cultured cells
In order to distinguish between tumour and endothelial cells in the co-culture model
endothelial cells were labelled for vWF in addition to KKS proteins. To allow for
simultaneous detection of vWF and either TK. BIR or B2R, a double immuno-enzymatic
procedure was employed. Mason and Sammons (1978) were the first to perform a
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simultaneous double immuno-enzymatic labelling procedure using peroxidase and alkaline
phosphatase to label two antigens simultaneously (373). For the present project, peroxidase
and alkaline phosphatase were used with DAB (Sections 2.3.2.2.4 and 2.3.2.3) and fast red
(Sigma) as substrates, respectively, and these chromogen systems were used sequentially,
rather than simultaneously, as described below. These chromogen systems could not be used
simultaneously for the proteins labelled as the antibodies specific for these proteins shared
the same host (a rabbit) with the exception of the TK antibody (derived from a goat). Thus,
simultaneous use of the chromogen systems would have resulted in cross-reaction.
I mmuno-chemistry on the cells of the co-culture model was performed as described in
Sections 2.3.2.2.4 and 2.3.2.3, respectively, up to and including incubation of the cells with
DAB chromogen. TK, B1R or B2R were labelled with DAB chromogen using antibody
dilutions that were optimal for dMVECs. Following inactivation of DAB in TBS/3%BSA,
the cells were blocked for 1 hour with IX milk blocker. This was followed by an overnight
incubation at 4°C with rabbit anti-human vWF IgG (diluted 1:200 with 1 X milk blocker).
Unbound antibody was washed off in TBS/3%BSA twice for 2 minutes each time. Cells
were then incubated with alkaline phosphatase-IgG conjugate (Sigma; diluted 1:50 with 1X
milk blocker) overnight at 4°C in a humidified chamber, followed by two 2-minute
TBS/3%BSA washes to remove unbound antibody. Next, cells were incubated with Fast
Red Solution [Sigma FastTM Fast Red TR/Napthol AS-MX (containing I mg/ml Fast Red,
0.4 mg/ml Napthol AS-MX, 0.15 mg/ml levamisole in 0.1 M Tris, pH 8.2)] in the dark at
room temperature for 5-7 minutes. This allowed the development of a red alcohol-soluble
precipitate due to the action of alkaline phosphatase on fast red. A 2-minute TBS/3%BSA
wash was performed twice to stop the reaction. Next, cells were stained with haematoxylin
as described in Section 2.3.2.2.4. The slides were mounted with aqueous jelly (thus sections
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were not dehydrated prior to mounting) as the reaction product of alkaline phosphatase and
fast red is alcohol-soluble (361).
2.3.2.5 Documentation of immuno-chemistry results
I mages of immuno-labelled control tissues and cells were taken with a DC280 digital
camera (I,eica) that was attached to the phase contrast, bright field microscope. Images were
digitised and recorded as 24-bit tagged image format files (TIFF). Magnification of images
(taking into account the magnification of the microscope objective and the digital camera)
was recorded. The digital camera was interfaced with AnalySIS ProTM 5 image analysis
software (Soft Imaging Systems, Germany), which allowed for analysis of images (Section
2.4).
2.3.3 Enzyme-linked immunoassay (ELISA) for TK
2.3.3.1 Background
The principle of ELISA is similar to that of immuno-chemistry where detectable antibodies
bind to target antigens. A brief description of the indirect sandwich ELISA (used for this
project) follows (374) (Figure 2.6). A primary antibody specific for the target antigen is
immobilised on a surface. The primary antibody is then incubated with the source of the
target antigen to allow binding. A second primary antibody is then allowed to bind to bound
antigen, creating a sandwich of antibody-antigen-antibody. A secondary antibody-marker
conjugate that will bind to the second primary antibody (Section 2.3.2.1) is then added to the
sandwich. The enzyme markers that may be used for ELISA are the same as those used for
immuno-chemistry (Section 2.3.2.1). For this project, alkaline phosphatase conjugated to
secondary antibody was used to convert disodium p-nitrophenyl phosphate (pNPP) into a
yellow product that could be quantified using a spectrophotometer.

 



















2.3.3.2 Controls for ELISA
Purified human urinary kallikrein (HUK) was the TK standard used. A composite standard
curve was generated from HUK (Calbiochem) standards of 5 ng/ml, 2.5 ng/ml, 1.25 ng/ml,
0.625 ng/ml, 0.3125 ng/ml and 0.156 ng/ml (Figure 2.7). For negative controls, HUK
standards and samples were replaced with PBS (Section 2.3.3.3).
2.3.3.3 ELISA protocol
The TK ELISA protocol described by Naidoo (2005) was followed (354). Briefly, the goat
anti-human TK antibody stock that was used for immuno-chemistry (Section 2.3.2.2.4) was
also used as the primary antibody in the TK ELISA. The stock solution of this antibody was
1 mg/ml. TK antibody was diluted to 30 ng/ml with coating buffer. Coating buffer
constituted 0.015 M sodium carbonate (Na2CO3 , Merck) and 0.04 M sodium hydrogen
carbonate (NaHCO 3 , BDH Chemicals, England) in ddH 2O and was adjusted to pH 9.6.
Diluted primary TK antibody was loaded into each well (100 Owen) of a 96-well
polystyrene ELISA microtitre plate (Corning Costar), and incubated at 4°C overnight to
allow coating of the wells. The wells were then washed with 200 1_11 0.01 M
PBS/0.05%Tween (Sigma) 3 times for 3 minutes each at room temperature to remove
unbound antibody. Wells were subsequently incubated with 200 pi of 0.5X milk blocker for
30 min at room temperature in order to block non-specific binding of antigen to coating
buffer. The PBS/Tween wash and 0.5X milk blocker incubation steps were repeated. Next,
100 of stored medium from the 2D challenge model (Section 2.2.6.1) was loaded onto the
plate. Five replicates were loaded for each sample. As a negative control, 100 IA of PBS
were loaded into 3 wells. HUK protein was serially diluted (5 ng/ml, 2.5 ng/ml, 1.25 ng/ml,
0.625 ng/ml, 0.3125 ng/ml, 0.156 ng/ml) with PBS on ice, and 100 p1 of each of these
standards was loaded in triplicate onto the plate (Section 2.3.3.2). After loading the samples,
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(Tecator, UK). This was followed by 3 PBS/Tween washes of 3 minutes each to remove
unbound TK antigen. Next, 100 ?Al of rabbit anti-human IgG TK antibody (1 mg/ml), diluted
to 25 ng/ml in 0.5X milk blocker, was loaded into every well and thereafter the plate was
incubated at 37°C for 1 hour in a shaking water bath. This rabbit anti-human IgG TK
antibody was also previously raised by the research unit in the Department of Clinical and
Experimental Pharmacology (refer to Section 2.1). After washing the wells with PBS/Tween
(3 times for 3 minutes each), 100 of anti-rabbit IgG-alkaline phosphatase conjugate
(Sigma) diluted 1:250 with 0.5X milk blocker was loaded into each well. The plate was
sealed with parafilm M (Whatman, UK) incubated at 37°C for 1 hour in a shaking water
bath. Following this, wells were washed 3 times with PBS/Twecn for 3 minutes each time in
order to remove unbound secondary antibody. Next, 100 of 1 mg/ml chromogenic
substrate, pNPP (Sigma), diluted in substrate buffer, was loaded. Substrate buffer was
prepared as 5 mM magnesium chloride (MgCl 2 , Merck) and 10% diethanolamine (Merck),
pH 9.6. The plate was kept in the dark at room temperature until a yellow colour developed
and absorbance (405 nm, Biorad (UK) Microplate Reader 3550 using Biorad Microplate
Manager 4.0 ® software) peaked between 1 and 1.5 units. The net absorbance readings for
the standards and samples were calculated by subtracting the mean blank (negative control)
absorbance from these readings. The TK concentrations of the various samples were
calculated from a standard curve of [TK] versus absorbance and expressed in ng/ml (Figure
2.7). Samples with TK concentrations below the range of the standard curve (i.e. with a net
absorbance of 0.0076) were considered to have 0 ng of TK per ml of medium. Graphs of
TK concentration (y axis) versus challenge percentage (x axis) were plotted.
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2.3.4 MTT cell proliferation assay
2.3.4.1 Background
MTT is reduced in metabolically active cells to form insoluble blue formazan crystals. which
may then be solubilised by a detergent (375). This blue colour can be quantified
spectrophotometrically at 595 nm. Since proliferating cells are metabolically more active
than non-proliferating cells, the MTT assay may be used to quantify cell proliferation.
2.3.4.2 Controls in the MTT assay
The MTT assay was performed following the challenging of cells with conditioned medium
(as described in Section 2.2.6.1), in order to determine the effect of challenge metabolites
(present in conditioned medium) on cell proliferation. In order to control for the effect that
cell-specific culture medium for one cell line might have on the proliferation of another cell
line, endothelial and tumour cells were also challenged with tumour and endothelial-specific
culture medium, respectively, in ratios of 0% (unchallenged), 10%, 25% and 50%. These
controls allowed for the net proliferative effect of challenge metabolites to be determined by
the subtraction of the proliferative effect of culture medium alone from the proliferative
effect of conditioned medium (culture medium + metabolites). Figure 2.8 shows the
experiment and control conditions for the MTT assay.
2.3.4.3 MTT assay protocol
Following the challenging of cells, medium was replaced with 110 vtl of a mix of MTT
solution and cell-specific medium (in a ratio of 1:10), and then incubated at 37°C/5% CO 2
for 4 hours (354). MTT solution was prepared as 5 mg MTT (Sigma) per ml of Hank's
balanced salt solution (HBSS, BioWhittaker). MTT-medium mix was then replaced by
100 IA DMSO and the plate incubated for 1 hour at 37°C/5% CO2 The absorbance of cells
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on a Biorad microplate reader using Biorad Microplate Manager 4.0® software. Cell
proliferation in the various challenge conditions was expressed as a percentage of the
unchallenged control, the mean absorbance of which represented 100% proliferation. The
net proliferative effect of challenge metabolites for the various challenge concentrations was
then calculated. The mean percentages of increase(+)/decrease(-) in proliferation (relative to
the unchallenged control) for the culture medium challenge controls (Section 2.3.4.2) were
subtracted from the proliferation percentages for the corresponding conditioned medium
challenge experiments. Graphs showing the net proliferative effect of challenge metabolites
(y axis) versus challenge percentage (x axis) were plotted.
2.4 Data analysis
For image analysis of immuno-labelled cells (from the challenge model), fields of view that
best represented the in vivo setting were chosen. For example, fields within the centre of a
large, tightly-packed congregation of dMVECs were not chosen as dMVECs do not form
large aggregates in vivo. However, images of such fields were not excluded for tumour cells,
as tumour cells form aggregates in vivo. Fields of view with similar cell shapes were chosen
and the 40X objective was used when taking all images in order to minimise the effect of
these variables on results. The extreme edges of the well were excluded as stain tended to
collect non-specifically in this area. From images taken, 15 cells were analysed for each
challenge condition for stain intensity and stain extent in various cell area categories. These
categories included (i) perinuclear area, cytoplasm, the membrane region and projections for
dMVECs, (ii) perinuclear cap, cytoplasm and projections for DU145 cells, and
(iii) cytoplasm and projections for MCF7 cells, as depicted in Figure 2.9.
The stain intensity was quantified using AnalySIS 5 ProTM image analysis software.





















scale of 256 phases. The entire stained area for each area category was selected with region
of interest circles (RICs). For each RIC, the mean grey scale intensity value and the area of
the RIC were calculated. The mean intensity of all the RICs for a particular area category
was calculated for each challenge condition. Values below 120 were considered to represent
background stain or no stain and were therefore excluded. The total cell area was calculated
by selecting the entire cell as a region of interest. Following this, the percentage area of the
cell that was stained was calculated as a measure of stain extent. The contribution of
staining in each area category to total stain extent was also calculated. Parametric analysis
of variance (ANOVA) with Tukey post-hoc testing (376, 377) was used to test for
significance (p<0.05) of difference among the stain intensities and among the stain extents of
the different challenge conditions (0%, 10%, 25% and 50 %).
The TK ELISA was performed twice (independently) with 5 replicates for each challenge
condition and ANOVA with Tukey post-hoc testing was used to test for significance
(p<0.05) of difference among secreted TK levels for the various challenge conditions.
Similarly, the MTT assay was performed at least twice (independently) with 5 replicates for
each challenge condition and ANOVA with Tukey post-hoc testing was used to test for
significance (p<0.05) of difference among cell proliferation rates for the various challenge
conditions.
Parametric ANOVA is based on the assumption that the population to which data belongs is
normally distributed, and that the standard deviations of the measurements of each treatment
group are similar. Thus, each time ANOVA was performed, the data was subjected to a
Kolmogorov-Smirnov normality test and Bartlett's standard deviation test. In cases where
the data failed Bartlett's standard deviation test, Kruskal-Wallis (the non-parametric
equivalent of ANOVA) with Dunn 's multiple comparisons test was used to test for statistical
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significance (p<0.05). Further, since 5 or more values are required to perform the standard
deviation and normality tests, Kruskal-Wallis with Dunn's multiple comparisons test was
used to test for significance (p<0.05) in cases where there were less than 5 values for the
projection area category for one or more of the challenge conditions. [Note: A least 3 or
more (3-7 cells) of the 15 cells analysed for each challenge condition for stain intensity and





CHAPTER 3 - RESULTS
3.1 Immuno-localisation: Controls
3.1.1 Tissue controls: TK, B1R and B2R
Tissues were immuno-labelled during cell culture immuno-labelling experiments in order to
validate the methodology and reagents used (Section 2.3.2.2). In the positive salivary gland
tissue control, the striated ducts labelled for TK, while acini, small intercalated ducts and
blood vessels with peroxidase-containing red blood cells remained unstained (Figure
3.1(i)A). Neurons of the dorsal horn of the spinal cord were strongly labelled for B1R in the
positive spinal cord tissue control (Figure 3.1(ii)A). B2R labelled in the thin limbs, thick
ascending limbs and collecting tubules of the kidney medulla in the positive kidney tissue
control (Figure 3.1(iii)A). Corresponding negative control tissues were unstained (Figure
3.1(i)B-(iii)B).
3.1.2 Cell culture controls: von Willebrand's factor (vWF), cytokeratin-19 (CK-19)
For positive cell culture controls, the different cell lines were each labelled for proteins
typically expressed by their respective cell types (Section 2.3.2.3). The dMVECs labelled
for vWF in their cytoplasm, membranes and small projections (Figure 3.2(i)A). The
presence of vWF in dMVECs indicated retention of function in these cells. Both DU145 and
MCF7 cells labelled for CK-19 in their cytoplasm and projections (Figure 3.2(ii)A-(iii)A).
Negative cell culture controls showed no staining (Figure 3.2(i)B-(iii)B).
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3.2 Immuno-localisation: TK, B1R and B2R and cell morphology in unchallenged
and challenged cells
3.2.1 Dermal microvascular endothelial cells (dMVECs)
Localisation of TK, B1R and B2R in both unchallenged and challenged dMVECs was
similar. Visually, these KKS proteins were labelled strongly in the perinuclear region and
large projections, less intensely in the surrounding cytoplasm and to varying degrees of
intensity in different regions of the membrane (Figure 3.3(i)-(iii)). There was a tendency to
stain in those areas of the membrane that were adjacent to, but not yet in contact with,
another cell (Figure 3.3(i)B; (ii)A; (iii)B). KKS-labelled, small projections were frequently
present, reaching from these stained membrane regions towards another cell. Stain was
generally less or absent where the membranes of cells had already made contact.
3.2.2 DU145 prostate tumour cells
The staining pattern for TK, BI R and B2R was similar in DU I45 cells whether unchallenged
or challenged with conditioned medium from dMVECs viz. a perinuclear cap of visually
intense stain and less intense stain in the surrounding cytoplasm and projections (Figure
3.4(i)A-C). However, in some cells with long thin projections, there was visually intense
staining throughout the cell (Figure 3.4(i)C).
In addition to observed staining patterns, some observations of DU145 growth patterns were
made. The DU145 cells tended to form small clumps in which cell nuclei were positioned
centrally and the cytoplasm of cells was directed outwards (Figure 3.4(i)B). Multinucleate
cells (Figure 3.4(i)D) and extremely large cells (Figure 3.4(0E) occurred in the control











3.2.3 MCF7 breast tumour cells
MCF7 cells characteristically had proportionately large nuclei and the little cytoplasm that
surrounded the nucleus formed long thin projections, which typically stained across the
entire length for TK, B1R and B2R (Figure 3.4(ii)A-C). The cytoplasm of MCF7 cells
stained entirely for the KKS proteins regardless of challenge condition.
Similar to DU145 cells, MCF7 cells tended to form clumps. In some of these clumps, cell
nuclei formed rings (Figure 3.4(ii)A). In contrast with the typical phenotypic characteristics
of MCF7 cells described above, a few cells had an extended area of cytoplasm (Figure
3.4(ii)B). These cells were more frequent in the challenge conditions when compared with
0% control condition. Multinucleate cells occurred occasionally, but the frequency of these
cells did not appear to be linked to challenge conditions.
3.3 Immuno-localisation: Image analysis in unchallenged and challenged cells
3.3.1 TK in dMVECs
Challenging dMVECs with tumour-conditioned medium (containing tumour cell
metabolites) resulted in a decrease in the intensity of stain for TK with increasing challenge
percentage, with the exception of the staining in dMVEC projections (Figure 3.5). There
was a highly significant decrease in stain intensity in the perinuclear and cytoplasm areas of
dMVECs challenged with DU145 metabolites (Figure 3.5(i)A-(ii)A, ANOVA p=0.0003 and
p=0.0007, respectively). Similarly, there was a highly significant decrease in stain intensity
in the perinuclear and cytoplasm areas of dMVECs challenged with MCF7 metabolites
(Figure 3.5(i)B-(ii)B, ANOVA p<0.0001 for both regions). Additionally, there was a
significant decrease in dMVEC membrane stain intensity when dMVECs were challenged
with MCF7 metabolites (ANOVA p=0.0057). In contrast, there was a tendency for
increased stain intensity for TK in the projections of dMVECs with increasing challenge
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(i)A. dMVEC-DU145, sample images B. dMVEC-MCF7, sample images
(ii)A. dMVEC-DU145, stain intensity B. dMVEC-MCF7, stain intensity
dMVEC- 0% 10% 25% 50% dMVEC- 0% 10% 25% 50%
DU145 MCF7
perinuclear 100 89.17 81.08 72.44 perinuclear 100 100.99 82.33 76.66
* (2.98) (4.07) (4.33) (5.60) * (2.31) (2.28) (4.12) (4.88)
cytoplasm 100 94.90 78.27 79.03 cytoplasm 100 96.60 74.03 75.76
* (3.69) (4.61) (5.63) (2.86) * (4.04) (4.93) (3.17) (4.43)
membrane 100 80.28 80.48 93.28 membrane 100 101.76 84.79 68.97
(11.76) (8.30) (9.56) (8.12) * (6.55) (8.28) (7.29) (6.15)
projections 100 113.63 114.21 123.21 projections 100 124.95 133.85 121.34
(14.34) (18.31) (5.11) (11.08) (10.89) (7.59) (12.39) (12.27)
* ANOVA, p 0.0057
(iii)A. dMVEC-DU145, stain extent B. dMVEC-MCF7, stain extent
* ANOVA, p 0.013
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ratios for both DU145 and MCF7-challenged dMVECs (with the exception of the 50%
MCF7-challenged dMVEC cells, which had a greater projection stain intensity than cells of
the 0% condition but less than that of the 25% challenge condition), however this trend was
statistically insignificant (Figure 3.5(ii)).
The extent of stain for TK tended to decrease in dMVECs that were exposed to tumour
metabolites (Figure 3.5). The extent of cytoplasmic stain (and therefore total stain extent)
diminished slightly with increasing exposure to DU145 metabolites, although this was not
statistically significant (Figure 3.5(iii)A). The extent of cytoplasmic and membrane stain
significantly decreased in MCF7-challenged dMVECs (ANOVA p=0.013 and p=0.0008,
respectively), thereby resulting in a significant decrease in total stain extent (Figure 3.5(iii)B,
ANOVA p=0.0104).
3.3.2 B1R in dMVECs
There were no significant changes in the intensity of stain for B1R in dMVECs that were
challenged with tumour cell metabolites when compared with their unchallenged
counterparts (Figure 3.6(i)-(ii)). The extent of stain for B1R in DU145-challenged dMVECs
decreased slightly with increasing challenge percentage, although this was not statistically
significant (Figure 3.6(iii)A). The differences in the extent of B1R in the membrane
category of DU145-challenged dMVECs for the various challenge conditions was overall
borderline statistically significant (Kruskal-Wallis p=0.045), however there was no
significant differences found between individually compared groups (i.e. with the Dunn 's
multiple comparisons post-hoc test). There were no significant changes in the extent of stain
for B 1R when dMVECs were challenged with MCF7 metabolites (Figure 3.6(iii)B).
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(i)A. dMVEC-DU145, sample images B. dMVEC-MCF7, sample images
(ii)A. dMVEC-DU145, stain intensity B. dMVEC-MCF7, stain intensity
dMVEC- 0% 10% 25% 50% dMVEC- 0% 10% 25% 50%
DU145 MCF7
perinuclear 100 98.85 98.46 105.48 perinuclear 100 94.92 101.62 94.11
(2.06) (3.35) (3.19) (2.34) (2.63) (2.84) (1.82) (3.17)
cytoplasm 100 94.14 81.00 101.59 cytoplasm 100 97.04 105.29 100.24
(5.62) (4.42) (4.23) (6.01) (5.49) (5.45) (4.84) (5.05)
membrane 100 80.42 64.22 80.79 membrane 100 136.71 100.03 124.06
(12.29) (9.66) (8.33) (12.98) (9.79) (15.21) (9.62) (10.42)
projections 100 92.13 98.90 98.68 projections 100 109.57 105.23 99.29
(6.19) (11.95) (3.02) (3.22) (7.69) (6.25) (24.08) (10.28)
(iii)A. dMVEC-DU145, stain extent B. dMVEC-MCF7, stain extent
* Kruskal-Wallis, p = 0.045
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3.3.3 B2R in dMVECs
There were no statistically significant changes in the intensity or extent of stain for B2R in
dMVECs that were challenged with tumour cell metabolites when compared with their
unchallenged counterparts (Figure 3.7). The mean intensities of staining in the projections
of MCF7-challenged dMVECs (10%, 25% and 50%) were greater than that of unchallenged
dMVECs; however, large variations in projection stain intensity occurred for all conditions
and this result was not statistically significant (Figure 3.7 (ii)B).
3.3.4 TK in tumour cells
The stain intensity for TK in the perinuclear caps and cytoplasm of DU145 cells was similar
for the 10%, 25% and 50% challenge ratios and significantly less than the stain intensity for
the 0% condition (Figure 3.8(i)A-(ii)A, ANOVA p=0.0093 and p=0.0039, respectively).
The intensity of stain in DU145 projections followed the same trend although it was not
statistically significant. The area of DU145 cytoplasmic stain for TK significantly decreased
with increasing challenge percentage (ANOVA p=0.012) and this largely contributed to a
significant decrease in total stain extent (Figure 3.8(iii)A, ANOVA p=0.0053). There were
also slight, statistically insignificant decreases in the extents of perinuclear cap and
projection stain. Overall, there was a tendency for decreased staining for 1K in challenged
DU145 cells.
Although the mean intensities of stain for TK were greater in challenged MCF7 cells when
compared with unchallenged counterparts. no statistically significant changes in stain
intensity occurred (Figure 3.8(i)B-(ii)B). Similarly, challenging MCF7 cells with dMVEC
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(i)A. dMVEC-DU145, sample images B. dMVEC-MCF7, sample images
(ii)A. dMVEC-DU145, stain intensity B. dMVEC-MCF7, stain intensity
dMVEC- 0% 10% 25% 50% dMVEC- 0% 10% 25% 50%
DU145 MCF7
perinuclear 100 101.85 96.86 96.03 perinuclear 100 99.51 97.14 95.85
(2.74) (3.72) (3.76) (2.6) (3.24) (3.04) (4.68) (3.38)
cytoplasm 100 96.64 90.04 97.94 cytoplasm 100 93.38 103.86 96.48
(4.17) (4.01) (5.55) (7.12) (6.29) (4.24) (8.36) (3.74)
membrane 100 92.61 81.59 111.73 membrane 100 105.46 84.54 95.48
(9.92) (9.52) (9.42) (13.90) (8.79) (7.37) (8.85) (8.83)
projections 100 81.42 97.25 93.79 projections 100 116.50 120.77 110.47
(2.37) (8.46) (3.25) (2.51) (15.93) (7.91) (17.32) (8.31)
(iii)A. dMVEC-DU145, stain extent B. dMVEC-MCF7, stain extent
B2R: dMVEC challenged with DU145,
stain extent
challenge %
B2R: dMVEC challenged with MCF7,
stain extent

























(i)A. DU145—dMVEC, sample images B. MCF7-dMVEC, sample images
(ii)A. DU145—dMVEC, stain intensity B. MCF7-dMVEC, stain intensity
DU145 —
dMVEC
0% 10% 25% 50% MCF7 -
dMVEC
0% 10% 25% 50%
perinuclear 100 84.91 86.99 89.51 cytoplasm 100 123.43 118.99 117.14
cap * (1.52) (4.01) (3.56) (3.40) (8.47) (4.87) (6.55) (6.76)
cytoplasm 100 68.58 75.13 70.53 projections 100 119.69 100.87 129.43
* (5.19) (7.53) (7.24) (6.33) (6.18) (6.87) (5.70) (5.09)
projections 100 59.78 65.93 66.10
(16.37) (11.60) (4.71) (20.35)
* ANOVA, p 0.0093
(iii)A. DU145—dMVEC, stain extent B. MCF7—dMVEC, stain extent
TK: MCF7 challenged with dMVEC, stain
extent
0 10 20 30 40 50 60
% challenge
* ANOVA, p 0.012
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3.3.5 B1R in tumour cells
Decreases in the stain intensity for B1R occurred in dMVEC-challenged DU145
cells (Figure 3.9(i)A-(ii)A). There was a statistically significant decrease in the perinuclear
cap stain intensity in cells of the 10% challenge condition when compared with that of
unchallenged cells (ANOVA p=0.0025). Challenged DU145 cells (10%, 25% and 50%
challenge conditions) had decreased cytoplasmic stain intensity (when compared with
unchallenged cells) that was most marked in the 10% challenge condition (ANOVA
p=0.014). The extent of stain for B1R was diminished in the cytoplasm of challenged
cells (ANOVA p<0.0001), resulting in a significant decrease in total stain that was most
diminished for the 50% challenge condition (Figure 3.9(iii)A, ANOVA p<0.0001). Overall,
there is evidently a trend for decreased stain intensity and extent for B I R in DU145 cells that
were exposed to dMVEC metabolites.
Challenging MCF7s with dMVEC metabolites did not result in significant changes in stain
intensity or extent of stain for B IR (Figure 3.9(i)B-(iii)B).
3.3.6 B2R in tumour cells
Staining in the cytoplasm of DU145 cells that were challenged with dMVEC metabolites
diminished with increasing challenge ratio, however this was not statistically
significant (Figure 3.10(i)A-(ii)A). Similarly, the stain intensity in the projections of DU145
cells of the 25% and 50% challenge conditions was decreased, although this was statistically
insignificant, when compared with unchallenged cells. There was a stepwise statistically
significant decrease in the extent of cytoplasmic stain in challenged DU145 cells (ANOVA
p=0.0004) that resulted in an overall significant decrease in total stain extent (Figure
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(i)A. DU145—dMVEC, sample images B. MCF7-dMVEC, sample images
(ii)A. DU145—dMVEC, stain intensity B. MCF7-dMVEC, stain intensity
DU145 -
dMVEC
0% 10% 25% 50% MCF7 -
dMVEC
0% 10% 25% 50%
perinuclear 100 82.20 94.66 98.31 cytoplasm 100 99.42 102.54 105.72
cap * (3.14) (4.46) (3.66) (2.4) (4.80) (4.90) (4.83) (3.68)
cytoplasm 100 62.43 93.55 75.15 projections 100 100.73 92.73 109.13
* (8.90) (12.62) (10.36) (6.79) (9.58) (11.26) (8.77) (6.89)
projections 100 84.45 66.65 104.97
(18.56) (13.99) (13.52) (44.53)
* ANOVA, p 0.014
(iii)A. DU145—dMVEC, stain extent B. MCF7—dMVEC, stain extent
* ANOVA, p < 0.0001
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(i)A. DU145—dMVEC, sample images
(ii)A. DU145—dMVEC, stain intensity B. MCF7-dMVEC, stain intensity
DU145 —
dMVEC
0% 10% 25% 50% MCF7 -
dMVEC
0% 10% 25% 50%
perinuclear 100 100.31 97.56 97.61 cytoplasm 100 98.45 98.26 107.46
cap (2.10) (1.64) (1.97) (2.09) (6.58) (6.16) (5.15) (6.56)
cytoplasm 100 87.45 79.5 71.09 projections 100 112.31 100.98 126.77
(11.88) (8.58) (7.24) (7.31) (8.24) (11.42) (9.77) (7.98)
projections 100 117.35 73.96 80.91
(13.59) (16.22) (9.28) (13.72)
(iii)A. DU145—dMVEC, stain extent
B2R: DU145 challenged with dMVEC,
stain extent
B. MCF7—dMVEC, stain extent
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Challenging MCI-7s with dMVEC metabolites did not result in any statistically significant
changes in the stain intensity or extent of stain for B2R (Figure 3.10(i)B-(iii)B). Although
the mean intensity of stain in the MCF7 projections of the 50% challenge condition was
considerably greater than that of unchallenged cells, no overall trend was observed for
projection staining intensity and no statistically significant differences were found between
the various challenge conditions (Figure 3.10(ii)B).
3.4 Immuno-localisation: TK, BIR and B2R in endothelial-tumour co-cultures
3.4.1 dMVEC-DU145 co-culture
DU145 cells stained intensely over the entire cell for TK, BIR  and B2R when co-cultured
with dMVECs while the staining pattern for these proteins in dMVECs co-cultured with
DU145 cells was similar to that in mono-cultured dMVECs (Figures 3.3 and 3.11(i)A-C).
TK, B 1 R and B2R were present in DU 145 projections that formed footplate-like connections
with dMVECs (Figure 3.1 1(i)A-C). Staining for these KKS proteins was also present in the
few dMVEC projections that connected with DU145 cells. There was a tendency for
dMVECs to increasingly form connections with one another, resulting in long chain-like
structures, when co-cultured with DU145 cells (Figure 3.1 I (i)D).
3.4.2 dMVEC-MCF7 co-culture
Similar to the dMVEC-DU145 co-cultures (Section 3.4.1), the MCF7 tumour cells labelled
intensely over the entire cell for TK, B1R and B2R while the staining pattern for these
proteins in dMVECs remained similar to that of dMVECs in mono-culture (Figures 3.3 and
3.11(ii)A-C). Staining for the KKS proteins was present in MCF7 projections that made
contact with dMVECs in the form of footplate-like ends (Figure 3.1 l(ii)A-C). Occasionally
dMVECs formed connections (that stained for TK, B1R and B2R) with MCF7 cells. As in
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(i) dMVEC-DU 145 co-culture
(ii) dMVEC-MCF7 co-culture
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The TK concentrations in the conditioned media of unchallenged DU145 cells and cells of
the 25% and 50% challenge conditions were similar (Figure 3.12C). Although, the TK
concentration for the 10% challenge condition was increased when compared with that for
unchallenged cells, this was not statistically significant. Similarly, the media of 10%
challenged MCF7 cells had an increase in TK concentration when compared with that in the
media of unchallenged MCF7 cells and cells of the other challenge conditions, however this
was not statistically significant (Figure 3.12D).
TK concentration in the conditioned media of unchallenged tumour cells was considerably
greater than that in the media of unchallenged dMVECs (Figure 3.12). However, 50%
DU145 and MCF7-challenged dMVECs secreted more TK than tumour cells and similar
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CHAPTER 4 - DISCUSSION
4.1 The KKS in endothelial cells
4.1.1 Unchallenged endothelial cells
The present study found that TK, B1R and B2R were expressed in cultured human
endothelial cells. While previous studies have shown TK and B2R to be consistently
expressed in cultured endothelial cells (286, 354, 378) and endothelial cells in vivo (189,
203); the expression of B1 R in cultured endothelial cells has not been consistently
demonstrated (286, 378) and in vivo expression of B1R only occurs to a significant extent in
pathological conditions (203). Expression of B1R in cultured endothelial cells in the present
study. and in some endothelial types in previous studies (256, 292, 354, 378), could possibly
be explained by the phenomenon of post-isolation induction. B1R induction following
isolation of tissues from the body is a well-known event that was first shown to occur in
rabbit aortic tissue (203). Therefore, it appears that, while TK and B2R are expressed in
endothelial cells physiologically, B 1 R is not significantly expressed in these cells although it
may be expressed in endothelial cells in a pathological environment, such as that of a
tumour.
In the present study, unchallenged endothelial cells (dMVECs) did not appear to secrete TK,
as measured by ELISA. However, this may be due to sensitivity limitations of the assay
rather than an absence of TK secretion from endothelial cells. Yayama et al. (2003)
demonstrated secretion of TK from HUVECs by western blotting of HUVEC-conditioned
medium using anti-human TK antibodies (379). Similarly, Naidoo (2005) demonstrated TK
secretion from HUVECs using the same methodology as that used in the present study (354).
Therefore, it seems likely that the unchallenged microvascular cells (dMVECs) used in the
present study secreted TK, although to a much lesser extent than HUVECs.
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Yayama et al. (2003) showed that the TK secreted by endothelial cells was active. In that
study, TK activity in the conditioned medium of HUVECs was demonstrated by cleavage of
the synthetic substrate Pho-Phe-Arg-4-methyl-coumaryl-7-amide and generation of kinin-
like contractile activity on rat uterus when incubated with kininogen and HUVEC-
conditioned medium, followed by inhibition of these effects by a specific TK inhibitor,
apronitin. This strongly suggests that TK secreted by endothelial cells is in an active form
and has kinin-generating ability. This is consistent with reports of protease conversion from
the inactive to active form occurring intracellularly (within the secretory pathway) as well as
extracellularly (203). It is possible that active TK secreted from endothelial cells may act on
localised kininogen, which is found bound to the surface of endothelial cells (HMWK) and
in plasma surrounding endothelial cells (LMWK) (171, 211), to produce kinins that then act
on endothelial cell B2R/B 1 R. However, it should be noted that although TK has been shown
to readily produce kinins from HMWK in vitro (171, 205-207), the well-accepted route of its
action is the generation of kallidin from LMWK (171). While both kallidin and bradykinin
may activate B2R, kallidin may also significantly activate B IR (203). In addition to kinin
generation followed by B I R/B2R signalling, active TK has been reported to directly activate
B2R, possibly via proteolytic cleavage (218), although this was not supported by a later
study (219). Endothelial cell B1R and B2R signalling following the secretion of active TK
may enhance angiogenic activities (354), as is discussed in detail later in Section 4.1.2.
Aside from kinin generation, TK may also cleave and activate other proteases involved in
angiogenesis (48, 242, 243) (Section 4.1.2). Since, in adults, angiogenesis is mainly a
pathological process that is controlled by a balance of pro and anti-angiogenic factors (39), it
appears reasonable that microvascular endothelial cells, which participate in angiogenesis in
vivo (347), secrete very little TK (a pro-angiogenic factor) under normal physiological
conditions.
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While TK, B1R and B2R immuno-labelled in the cytoplasm region of endothelial cells in the
present study [and in previous studies (286, 354)], it was of particular interest that these
proteins were also localised in (i) large projections of endothelial cells and (ii) in specific
endothelial cell membrane regions in relation to surrounding cells and in small projections
arising from these membrane regions, as discussed below. It should be noted that while
labelling for 131 R and B2R was observed in various regions of the cell, these receptors are
actually present in the plasma membrane (i.e. on the cell surface) (260).
(i) The intense labelling of TK, BIR and B2R in the large projections of endothelial cells
was consistent with the finding of Plendl et al. (2000) who demonstrated intense TK
labelling in projections of bovine aortic endothelial cells (286), and Naidoo (2005) who
demonstrated intense labelling for TK, BIR and B2R in HUVEC projections (354). Since
invasive cell migration is initiated by the growth of long cellular
extensions/projections (380), the localisation of the KKS proteins in large projections of
endothelial cells suggests a role for the KKS in the migration and invasion of these cells,
which occurs during angiogenesis (39). Although specific involvement of the KKS in
endothelial cell migration has not been demonstrated thus far, there are many possible
mechanisms by which the KKS may promote migration and invasion of endothelial cells
during angiogenesis. For example, TK secreted from endothelial cell projections may cleave
and activate MMP-2 (242) and MMP-9 (243). These MMPs may then cleave ECM
components thereby facilitating cellular invasion of the ECM (19). In particular, MMP-2,
which is bound to a v i33 on the surface of angiogenic endothelial cells allows for localised
degradation of the ECM as these cells migrate (68). Further, secretion of TK from the
endothelial cell projections, followed by activation of MMPs would localise ECM-degrading
activity to the leading edge of movement (i.e. the projection). It is also possible that TK
secreted from endothelial cell projections may directly cleave the ECM at the leading edge
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of movement, thereby facilitating endothelial cell invasion of the ECM. Direct cleavage of
the ECM by TK has not been demonstrated thus far, however, a previous study has
suggested TK involvement in ECM cleavage (241) and several kallikreins have been shown
to directly cleave the ECM (172). TK secreted from endothelial cell projections may also
generate kinins from localised kininogen bound to the surface of endothelial cells or in
plasma surrounding endothelial cells resulting in B1R/B2R signalling in endothelial cell
projections (as discussed earlier). B1R/B2R signalling results in the production of NO (203)
which, via modulation of FAK phosphorylation, is important in the regulation of endothelial
movement (133). FAK phosphorylation [which may be mediated by B1R (260)] results in
recruitment of focal adhesion proteins, formation of focal adhesion complexes and
stabilisation of adhesion (25). Localisation of this activity to the endothelial cell projection
would result in attachment of the projection to the ECM. Attachment to the ECM is required
at the leading edge of movement (the projection) in order to provide traction to pull the cell
forward while detachment of adhesions at the trailing edge allows forward motion (20, 380).
Thus, the localisation of KKS proteins in large projections of endothelial cells supports the
role of the KKS in angiogenesis.
(ii) In the present study, KKS labelling was also observed in endothelial cell membrane
regions that were adjacent to, but not yet in contact with, other endothelial cells as well as in
small projections that extended from these labelled areas towards other endothelial cells.
This suggests that the KKS is involved in the initiation of cell-cell contact in endothelial
cells. Accordingly, KKS proteins were generally absent or less in regions of the cell
periphery that already had well-established contact with another cell.  Folkman and
Haudenschild (1980) demonstrated that the alignment and connection of endothelial cells
with one another, such that their autolytic vacuoles (present in the cytoplasm) form a
continuous tube, is necessary for capillary tube formation (71). Additionally, the formation
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of endothelial cell contact with pericytes is necessary for vessel formation (136). Thus, the
involvement of the KKS in initiating endothelial cell contact with other endothelial cells, and
possibly with other cell types, suggests that the KKS could potentially play a role in
establishing capillary tube formation during the latter stages of angiogenesis. In support of
this, a previous study has shown inhibition of HUVEC cord formation on matrigel by 13K
antagonists (293).
4.1.2 Challenged endothelial cells
A major finding in the present project was that when endothelial cells were challenged with
prostate and breast tumour metabolites, intracellular TK significantly decreased, as indicated
by the diminished intensity and extent of stain for TK, and this was accompanied by a
significant increase in TK in the conditioned media. This indicates that the decrease in
intracellular TK in challenged endothelial cells was most likely due to tumour-induced
secretion of TK by endothelial cells into the medium.
Previous studies support tumour-induction of TK secretion by endothelial cells. HUVECs
that were challenged with neuroblastoma and cervical carcinoma metabolites had decreased
intracellular TK and increased extracellular TK (secreted into the medium) when compared
with unchallenged HUVECs (354). Stadnicki et al. (1998, 2003) have shown, although not
conclusively, increased TK secretion by intestinal goblet cells and macrophages with a
concomitant decrease in TK in intestinal tissue in both rat enterocolitis and human
inflammatory bowel disease (specifically Crohn's disease) (188, 270). Those studies
provide evidence that TK secretion increases in chronic inflammatory conditions, which
include cancer (43). Contrary to these findings, Plendl et al. (2000) found increased proTK
in bovine angiogenic endothelial cells of the mature corpus luteum in comparison to non-
angiogenic cells and no significant difference in intracellular TK levels between them (286).
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However, TK secretion from these cells was not quantified. It is possible that increased
proTK in angiogenic cells indicated increased expression of the TK gene; however, no
corresponding increase in intracellular TK could suggest increased secretion of TK. Other
studies have shown that tumour cells may induce the release of angiogenic factors other than
TK from various cell types, including endothelial cells. Examples of this are the increased
VEGF levels which occurred in the culture medium concomitant with decreased VEGF
levels in hepatocytes when these cells were co-cultured with neuroblastoma cells (381), and
the finding that microvascular endothelial cells secreted significantly increased amounts of
MMP-2 when co-cultured with prostate tumour cells (382).
Since TK may be secreted from endothelial cells in an active form (379), the upregulation of
TK secretion from endothelial cells exposed to prostate and breast tumour metabolites
implies increased extracellular TK activity in these tumour environments. As discussed
earlier (Section 4.1.1), active TK may generate kinins from local kininogen resulting in the
activation of endothelial cell kinin receptors, and TK may also directly activate endothelial
cell B2R. Previous in vitro studies have shown that the activated endothelial cell kinin
receptors are involved in signalling angiogenic activities such as endothelial cell
proliferation (256, 292, 293) and cord formation (254, 293). Kinin receptor signalling has
also been shown to potentiate that of VEGF receptors and bFGF receptors in endothelial
cells (249, 254, 256). Since VEGF is involved in mediating all steps of the angiogenic
cascade (39, 58, 78, 81) and since bFGF has been shown to stimulate endothelial
proliferation, migration and capillary tube formation in vitro (39, 68), involvement of the
kinin signalling in all stages of angiogenesis is likely. The role of kinin receptor signalling
in angiogenesis is further supported by in vivo studies using mouse models that have shown
significant suppression of angiogenesis by both a 131 R antagonist (292) and a B2R
antagonist (383). Endothelial cell kinin receptor signalling also results in increased capillary
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permeability (203, 246), which is important for the infiltration of inflammatory cells and
therefore initiation of inflammation (266, 267). Kinins produced by active TK in the tumour
environment may also act on stromal cells to enhance chemotaxis and activation of
inflammatory cells (118, 268). Since inflammation is a promoter of angiogenesis and these
two processes often occur concomitantly (97, 106, 107), it is likely that the pro-inflammatory
effects induced by kinins in the tumour environment would potentiate angiogenesis. Aside
from the generation of kinins, active TK secreted by endothelial cells may upregulate
proteolytic activity in the tumour environment either directly or via the activation of MMPs
(242, 243). Proteolytic activity not only facilitates the migration and invasion of endothelial
cells via enhancing ECM cleavage, but also plays a role in other aspects of the angiogenic
cascade. For example, MMPs play an important role in capillary tube formation (180) and
they may cleave and activate growth factors and growth factor receptors that are involved in
endothelial cell proliferation and capillary tube formation (48, 68). Further supporting the
role of TK as a promoter of angiogenesis, TK gene therapy promoted angiogenesis in
ischaemic mouse (287) and rat models (289), corrected impaired angiogenesis in
spontaneously hypertensive rats (288) and protected rats from ischaemic injury when
administered after the onset of a stroke (290). Therefore, it is postulated that a tumour-
mediated increase in TK secretion by endothelial cells would upregulate angiogenesis,
thereby promoting prostate and breast tumour progression. The TK secreted by endothelial
cells exposed to tumour metabolites may also promote tumour progression by directly
influencing tumour cell activities and this is discussed in detail in the following section on
tumour cells (Section 4.2.1).
Although there was a significant overall decrease in intracellular TK in challenged
endothelial cells and TK decreased in the cytoplasm, perinuclear and membrane regions of
these challenged cells, this did not apply to TK staining in the projections of challenged
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endothelial cells. It was interesting that TK tended to increase in endothelial cell projections
with increasing exposure to prostate and breast cancer cell metabolites, although this was not
a statistically significant trend. This finding suggests that tumour metabolites may recruit
TK to the endothelial cell projections. Considering the presence of all the KKS components
in the region of the endothelial cell projections and the implication of KKS activity in cell
migration, it appears that tumour metabolites could promote endothelial cell migration via
this mechanism. This would further contribute to tumour angiogenesis and therefore tumour
progression.
Although intracellular TK decreased significantly in challenged endothelial cells,
intracellular B1R and B2R levels in endothelial cells were not significantly affected by
exposure to prostate and breast tumour cell metabolites. These findings are consistent with
the unchanging intracellular B1R and B2R levels in HUVECs challenged with
neuroblastoma metabolites in a previous study (354). However, since inflammatory
cytokines and growth factors upregulate the expression of B1R and B2R (203), it is likely
that the expression of B1R and B2R would be increased in endothelial cells exposed to the
inflammatory environment present in the stroma of prostate and breast tumours (12, 43).
Exposure of endothelial cells to prostate and breast tumour cell metabolites significantly
increased their proliferation (with the exception of the 25% MCF7-challenged dMVECs).
These findings are consistent with those of a previous study in which HUVEC proliferation
was greatly and significantly increased by neuroblastoma and cervical carcinoma cell
metabolites (354). Also in support of increased endothelial cell proliferation induced by
tumour cells, are the results of a previous study showing increased proliferation of
endothelial cells following exposure to conditioned medium of progcstin-treated breast
cancer cells (384).
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TK secreted from challenged endothelial cells [as well as TK secreted by prostate and breast
tumour cells (Section 4.2.1)] may have contributed to the observed increase in proliferation
of challenged endothelial cells. As discussed earlier, tumour-induced TK secreted from
endothelial cells may activate endothelial cell kinin receptor signalling. The contribution of
increased extracellular TK to upregulation of endothelial cell proliferation is supported by in
vitro studies that demonstrate a role for kinin receptors in endothelial cell proliferation (256,
292). Further, it has been demonstrated in an in vivo study that B2R contributes to
endothelial cell proliferation (294). Since endothelial cell proliferation is a necessary step of
angiogenesis, it appears that tumour-induced endothelial cell proliferation (possibly
involving TK) is a mechanism of promoting angiogenesis in prostate and breast tumours. In
the present study, endothelial cell proliferation may also have been stimulated by VEGF, an
important endothelial cell growth factor and initiator of angiogenesis (39, 81), which may be
released by both DU 145 and MCF7 cells (385, 386).
4.2 The KKS in tumour cells
4.2.1 Unchallenged tumour cells
The present study found that TK, B1R and B2R were expressed in cultured DU145 prostate
tumour cells. This is consistent with previous reports of TK and B2R in cultured prostate
cancer cells (274) and the expression of B I R in malignant prostate tissues and cultured
prostate cancer cells (260). While TK and B2R are expressed in both the normal prostate
and in prostate cancer (260, 274), B I R is only expressed in prostate cancer (260), suggesting
a role for B1R in prostate tumourigenesis. It has been suggested that B 1 R may be used as a
marker for pathological growth of the prostate in addition to other kallikrein markers already
in use (260), the most important clinical marker being PSA/kallikrein 3 (172).
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TK, 131 R and B2R were also expressed in MCF7 breast tumour cells in the present study.
The presence of TK in breast cancer tissue has been demonstrated previously (325, 387), and
B1R and B2R have been detected in cultured breast tumour cells (327, 388). TK and B2R
are also expressed in normal breast tissue (325, 326), although B1R is not. Specific
expression of B I R in breast cancer cells indicates that B1R is involved in breast
tumourigenesis.
In contrast to unchallenged endothelial cells, both prostate and breast tumour cells secreted
amounts of TK that were detectable by ELISA in the present study. The secretion of TK by
these tumour cells in conjunction with tumour-induced TK secretion from endothelial
cells (Section 4.1.2) and 13 I K and B2R expression in tumour cells, suggests the presence of
an active KKS in these tumour types. Although the kininogen component of the KKS was
not demonstrated in the present study, it is expected that kininogen is abundant in the tumour
environment. LMWK and HMWK in tumours could be provided by extravascular
fluid (171, 211), which is abundant in tumours due to the high permeability of tumour blood
vessels (12). Neutrophils present in the inflammatory reaction in the tumour stroma (266),
are a source of both HMWK and LMWK (210). Additionally, endothelial cells in the
tumour environment could act as a source of HMWK (171). Therefore, tumour-derived TK,
or TK derived from endothelial cells exposed to tumour metabolites (in the tumour
environment), may generate kinins from kininogen present in the tumour environment and
thereby activate tumour cell kinin receptors. This, in addition to TK-mediated upregulation
of proteolytic activity, may have pro-tumourigenic effects, a discussion of which follows.
TK-mediated kinin generation from kininogen present in the tumour environment may signal
the proliferation of prostate and breast tumour cells (260, 327), and the migration and
invasion of prostate tumour cells (260), which are necessary steps in the process of tumour
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progression (13). KKS involvement in prostate tumour cell migration and invasion was
suggested by B1R-mediated migration of these cells on a 2D surface and invasion of
fibronectin by these cells in a previous study (260). This is additionally supported by
immuno-labelling for TK, B I R and B2R in DU145 prostate tumour cell projections in the
present study. Likewise, the presence of TK, I31R and B2R in the projections of MCF7
breast tumour cells in the present study indicates probable KKS involvement in breast cancer
cell invasion and migration. TK participation in breast cancer invasion and migration was
demonstrated in a previous study, in which an inhibitor of TK, FE999024 reduced invasion
of matrigel by breast tumour cells and pulmonary extravasation in an ex vivo rat
model (241). However it is not known whether TK acted directly in this instance, through
MMP activation, through kinin generation followed by kinin receptor activation, or via more
than one mechanism. Due to the presence of B 1 R and B2R in the MCF7 projections in the
present study, it would appear that kinin receptor activation could be a mechanism by which
TK promotes breast cancer cell migration and invasion. TK present in the tumour
environment may also activate MMPs (242, 243), which may promote the growth, migration
and invasion of tumour cells (19). Involvement of MMP-2 specifically in breast cancer
epithelial cell migration has been suggested by a previous study (164). Further, the
enhancement of inflammation in the tumour environment resulting from upregulated
extracellular TK activity (Section 4.1.2), facilitates tumour progression via promoting cell
proliferation amongst several other mechanisms (43) (discussed in detail in Section 1.1.1.3).
It is also postulated that the upregulation of TK in prostate and breast tumour environments
(via tumour-induced endothelial cell TK secretion in addition to TK secreted by tumour
cells) may be a mechanism for progression of these tumours to AI and 01 forms,
respectively. Kinin receptor signalling as a result of TK-mediated kinin generation, may
potentiate the signalling of bFGF receptors (256, 257) and EGF receptors (259, 260). FGF
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and EGF, are important in the development of prostate and breast cancer, respectively (308,
311, 389), and have also been implicated in the development of Al and 01 forms of these
cancers, respectively (49, 197, 302, 311). There are also other examples of KKS
potentiation of growth factors that are involved in the development of Al and 01 cancers and
this was reviewed extensively in Section 1.1.3.3.2.6.2. Therefore, it is plausible that
increased TK in the environment of prostate and breast tumours would contribute to the
development of hormone-independence. Although the MCF7 breast cancer cells used in the
present study were oestrogen-dependent (390), the DU 145 prostate cancer cells used were
Al (260, 391). In addition, (i) demonstration of kinin-mediated (via the BIR) growth,
migration and invasion of Al prostate cancer cells (260), (ii) B2R involvement in Al prostate
tumour cell proliferation (324), (iii) the suppression of AI prostate tumour growth by BK
antagonists in a nude mice model (293), and (iv) TK-mediated invasion of 01 breast cancer
cells (241), support this hypothesis.
The contribution of increased TK activity in prostate and breast tumour environments, as
indicated by the present study, to prostate and breast tumour-associated
angiogenesis (Section 4.1.2), tumourigenesis and possibly progression to hormone-
independent cancers, has therapeutic implications. KKS antagonists may be useful in
treating prostate and breast cancer, particularly hormone-independent forms of these cancers
for which there is currently no satisfactory therapy (49, 299, 300, 303). A BK antagonist,
B9870, is already in pre-clinical development for treatment of prostate cancer at the US
National Cancer Institute in their RAID program (392). Considering the upregulation of
endothelial cell TK secretion by breast cancer cell metabolites, BK antagonists might also be
effective in inhibiting breast tumour growth. Further, considering (i) the success of
kallistatin (a TK inhibitor) in suppressing angiogenesis and inflammation [both of which are
necessary for tumour progression, (39, 43)] in vivo, (ii) the effectiveness of TK in inducing
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angiogenesis in vivo (287-290), and (iii) the upregulation of extracellular TK by breast and
prostate cancer cells in the present study, specific TK antagonists may be useful in treating
these cancers.
4.2.2 Challenged tumour cells
TK, B1R and B2R levels in breast tumour cells, as well as TK secretion from and
proliferation of these cells, were not significantly affected by exposure to endothelial cell
metabolites. However, in challenged prostate cancer cells there was an overall decrease in
intracellular TK. B 1 R and B2R. The reason for this is not clear. However, it would appear
that this result is of limited significance since (i) the output of secreted TK from prostate
tumour cells was not significantly diminished by endothelial cell metabolites in the present
study [supporting this, HUVEC metabolites had no significant effect on TK secretion by
neuroblastoma and cervical carcinoma cells (354)], (ii) other factors in the in vivo
environment of the tumour, such as inflammatory growth factors and cytokines [these may
increase B I R and B2R expression (203)), could counteract the endothelial-mediated
decrease in the prostate tumour cell kinin receptors, rendering it insignificant in vivo, and
(iii) several previous studies (in vitro and in vivo) have shown that kinin receptors play an
important role in the growth of prostate tumours (259, 293, 324) and in the present study
prostate tumour cell proliferation was not significantly affected by exposure to endothelial
cell metabolites.
4.3 The KKS in endothelial -tumour co-cultures
Although KKS proteins were localised in the same regions of endothelial and tumour cells in
co-culture as in these cells in mono-culture, the presence of KKS proteins in the endothelial
cell projections that were in contact with tumour cells and in the projections of tumour cells
that connected with endothelial cells was a noteworthy finding of the present study. Naidoo
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(2005) also demonstrated KKS proteins in the contact points between endothelial cells
(HUVECs) and tumour cells (neuroblastoma cells) (272, 354). The presence of the KKS in
contact points between tumour and endothelial cells indicates that the TK secreted by tumour
cells and endothelial cells (stimulated by exposure to tumour cell metabolites) results in
localised activation of the B IR and B2R on both cell types. As discussed earlier, it is
plausible that kininogen is present in the vicinity of the tumour-endothelial contact point,
allowing for localised kinin generation, and TK may also directly activate the B2R. The
signalling from endothelial and tumour cell kinin receptors (B1R/B2R) that follows may
result in several pro-angiogenic and pro-tumourigenic activities, as was discussed in detail in
Sections 4.1.2 and 4.2.1, respectively.
The increased connection of endothelial cells with one another to form chain-like structures
in endothelial-tumour co-cultures, as well as circular structures in dMVEC-MCF7 co-
cultures, was an interesting observation in the present study. Although this phenotypical
arrangement of endothelial cells was not observed when endothelial cells were challenged
with tumour cell metabolites, in the co-cultures this arrangement was observed when tumour
cells were not necessarily in direct contact with endothelial cells. Thus, this finding in the
co-cultures may be due to endothelial exposure to increased tumour cell metabolites secreted
at close range, and is suggestive of the ability of tumour metabolites to stimulate
angiogenesis. The ability of tumour cell metabolites to induce angiogenesis was shown by
the study of Folkman and Haudenschild (1980), in which endothelial cells, cultured in
tumour-conditioned medium, arranged themselves over a period of weeks into capillary-like
structures (71). An additional observation made in the present study, was that occasionally
the circular endothelial structures in dMVEC-MCF7 co-cultures enclosed breast tumour
cells. This hints at the ability of breast tumour cells to attract differentiating endothelial
cells, which may then form blood vessels and provide a route for metastasis (39).
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4.4 Summary and conclusions
In summary, the present study shows that prostate and breast tumour cell metabolites
increase the secretion of TK from endothelial cells, and that these tumour cells also secrete
TK. This indicates upregulation of TK extracellular activity in prostate and breast tumour
environments. The activities of TK including (i) proteolytic activation of MMPs,
(ii) possible direct cleavage of ECM components, and (iii) direct activation of kinin receptors
or indirect activation of these receptors via kinin generation, may result in endothelial cell
proliferation, migration, invasion and capillary tube formation. The involvement of the KKS
in these angiogenic activities is supported by the following findings of the present study:
(i) the localisation of TK, B1R and B2R in large projections of endothelial cells and (ii) in
small projections that establish endothelial cell-cell contact, and (iii) the increase in
endothelial cell proliferation in conjunction with increased endothelial cell TK secretion (in
response to tumour metabolites). The activities of TK may also promote tumourigenesis by
stimulating the proliferation, migration and invasion of tumour cells, as is supported by
localisation of KKS proteins in the projections of prostate and breast tumour cells in the
present study. The localisation of KKS proteins in heterogeneous tumour-endothelial cell
contacts in the present study also suggests a role for these proteins in tumour-endothelial cell
interactions, which may be involved in promoting angiogenesis and tumourigenesis.
Another consequence of increased extracellular TK activity would be enhancement of
inflammation in these tumours, thereby further stimulating angiogenesis and tumourigenesis.
It is also possible that upregulated TK activity in these tumour environments may assist in
the development of Al (as supported by the Al characteristic of DU145 prostate tumour cells
used in the present study) and ()I forms of prostate and breast cancer, respectively, for which
therapy is currently inadequate. Thus, KKS antagonists, some of which are already in pre-
clinical development for the treatment of prostate cancer, have potential for use in the
treatment of prostate and breast cancer, including hormone-independent forms of these
1 3 3
cancers. The main findings and implications of the present study, in relation to previous
studies, are summarised in Figure 4.1. In conclusion, the findings of the present study
support the hypothesis that the KKS promotes tumour-associated angiogenesis and




































The results of the present study, in conjunction with previous studies, provide evidence for
upregulated KKS activity with pro-angiogenic and pro-tumourigenic effects in prostate and
breast tumours; however, this could be more definitively established by studies using KKS
antagonists.
Firstly, an increase in endothelial cell kinin receptor signalling due to prostate and breast
tumour metabolites could be confirmed by measurement of ERK phosphorylation and
inositol phosphate production in: (i) unchallenged endothelial cells with no exposure to
antagonists, and (ii) endothelial cells challenged with tumour metabolites and not exposed to
antagonists or exposed toTK/B1R/B2R-specific antagonists or exposed to all 3 KKS
antagonists. Specific TK, 131 R and B2R antagonists are available (203, 241). ERK
phosphorylation and inositol production may be used as indicators of kinin receptor
signalling (324). These events are also part of other signalling pathways; however, ERK
phosphorylation and inositol production due to other signalling pathways would be a
background constant and comparison with controls not exposed to antagonists would
account for this. This experimental design should allow assessment of the effect of tumour
metabolites on the activity of each component of the KKS separately and as a whole.
However, the activity of TK apart from its indirect or direct activation of kinin receptors
cannot be assessed by this proposed study.
After establishing/confirming the effect of prostate and breast tumour metabolites on
endothelial cell KKS activity, the role of tumour-induced upregulated KKS activity in the
angiogenic events of endothelial cell proliferation, migration and invasion and cord/tube
formation could be further confirmed using microvascular endothelial cells. This could be
achieved by performing a proliferation assay (such as the one used in the present study), as
1 36
well as a migration assay [e.g. the wound healing assay, (260)], invasion assay [e.g. Boyden
chamber assay, (338)] and cord formation assay [using matrigel, (338, 345)] on
microvascular endothelial cells with and without exposure to TK, B 1 R and B2R antagonists.
Some in vitro studies have already shown involvement of the some of the KKS components
in these endothelial cell activities, although not necessarily using microvessel cells (254,
256, 292, 293). The contribution of TK to specific steps of the angiogenic cascade, and the
specific involvement of 131R and B2R in endothelial cell migration and invasion have yet to
be established.
Similarly, to confirm a role for the KKS in the proliferation, migration and invasion of
prostate and breast tumour cells, these assays could be performed on tumour cells with and
without KKS antagonist exposure. Such a study has been conducted with a BIR antagonist
and AI prostate cancer cells using proliferation, migration and invasion assays, confirming
the role of B1R in prostate cancer and possibly the development of AI cancer (260). If the
proposed study were to be conducted with 01 breast cancer cells it could provide evidence
for a role of the KKS in the development of 01 cancer. Evidence has already been provided
for TK involvement in the invasion of 01 breast cancer cells (241). The involvement of B2R
in breast cancer proliferation (326) and the proliferation of Al prostate cancer cells (324) has
also been demonstrated. However, the roles of the B I R in breast tumourigenic activities,
and B2R and TK in other prostate/breast tumourigenic activities have yet to be confirmed.
The proposed studies discussed above could also be performed for other cancer types in
which KKS expression has been demonstrated (273 -277, 279, 280, 283, 284).
Evidence provided by the present study and previous studies for the involvement of the KKS
in prostate and breast tumour-associated angiogenesis and tumourigcnesis, particularly in Al
and 01 forms of these cancers, has therapeutic implications (Section 4.2.1). In vivo studies
1 37
that test the effectiveness of KKS inhibitors in inhibiting development of breast and prostate
cancer are required. Promising in vivo studies that show potent inhibition of prostate cancer
by BK antagonists, have recently led to pre-clinical development of one of these
antagonists (Section 4.2.1). Considering the upregulation of endothelial TK secretion by
breast cancer cells, in vivo studies using these BK antagonists in an attempt to inhibit breast
cancer development should be conducted. Additionally, the results of the present study, as
well as the previous demonstration of the effectiveness of kallistatin (a TK inhibitor) in
inhibiting angiogenesis and inflammation in vivo (Section 4.2.1), suggest that the
effectiveness of TK inhibitors in inhibiting growth of breast and prostate tumours should be
tested in an in vivo model.
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